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ABSTRACT 
 
Malignant gliomas and especially glioblastomas are devastating tumors of the central 
nervous system with no effective treatment currently available. Oncolytic virotherapy, in 
which replicative viruses that selectively destroy cancer cells are employed, offers a new 
promising strategy for the treatment of glioblastomas. Consequently several viruses with 
oncolytic potency have been extensively researched, and some have reached phase I/II 
clinical trials. In these trials, oncolytic viruses have shown a good safety profile. However, 
the efficacy of virotherapy has been poor. This could be partly explained by the attenuated 
replication phenotype of the currently used therapy viruses. The aim of this thesis was to 
evaluate the oncolytic potency of naturally attenuated strains and engineered clones of 
Semliki Forest virus (SFV, genus: Alphavirus) in mouse syngeneic glioma models and to 
outline useful strategies to inhibit SFV replication in healthy cells.  
In the first part of the thesis it was shown that the naturally neuroattenuated SFV vector 
VA7, which was previously shown to potently eradicate human glioma xenografts in 
immunodeficient mice, was totally ineffective against mouse GL261 gliomas in 
immunocompetent host. The resistance of cancer cells to VA7 was attributed to type I 
interferon (IFN) -mediated antiviral response. To overcome this resistance, novel strategies 
to safely harness the increased replication potency of neurovirulent SFV4 strain were 
evaluated. In the second part, targeted deletion of host cell amphiphysin binding regions of 
viral non-structural protein 3 was introduced in order to reduce SFV4 neuropathogenicity. 
However, neuron-specific inhibition of SFV4 could not be achieved. In the third part, 
neuronal replication of SFV4 was successfully restricted by incorporation of target 
sequences against neuron-expressed microRNA-124 into the virus genome (SFV4-
miRT124). In the fourth part, SFV4-miRT124 was used to target previously resistant CT-2A 
mouse gliomas. Notably, SFV4-miRT124 similarly to parental wild-type virus displayed 
tolerance to type I IFN in glioma cells. This beneficial phenotype correlated with increased 
oncolytic potency in vivo. 
As a conclusion, type I IFN resistance of neurovirulent alphavirus SFV4 could be 
harnessed to increase the efficacy of therapy in mouse glioma model. The results indicate 
that provide a clearly promising rationale for addition of novel oncolytic alphaviruses to 
the growing arsenal of clinical viral vectors.  
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TIIVISTELMÄ 
 
Glioblastoomat ovat pahanlaatuisia keskushermoston kasvaimia, joihin ei ole olemassa 
toimivaa hoitomuotoa. Uuden mahdollisuuden glioblastooman hoitoon tarjoaa 
onkolyyttinen viroterapia, jossa kasvainsoluissa lisääntyviä viruksia käytetään 
kohdennetusti syöpäkudoksen tuhoamiseen. Lupaavien prekliinisten tulosten ansiosta 
useiden eri virusten tehoa glioblastooman hoidossa on selvitetty faasi I/II kliinisissä 
kokeissa. Näissä kokeissa onkolyyttiset virukset on havaittu turvallisiksi mutta 
hoitoteholtaan heikoiksi. Yksi heikkoa hoitotehoa selittävä tekijä on käytettyjen virusten 
heikennetty lisääntymiskyky. Tämän väitöskirjatyön tavoitteena oli selvittää alfaviruksiin 
kuuluvan Semliki Forest -viruksen (SFV) muokattujen kloonien onkolyyttistä tehoa hiiren 
syngeenisissä glioomamalleissa ja mahdollisia tapoja estää SFV:n patogeenisyyttä hiiren 
keskushermostossa. 
Väitöskirjan ensimmäisessä osatyössä havaittiin, että luontaisesti heikennetty SFV-
vektori VA7 ei kyennyt tuhoamaan syngeenisiä GL261-glioomia immunokompetentissa 
hiirimallissa. Hoitoresistenssin osoitettiin liittyvän kasvainsoluissa toimivaan tyypin I 
interferonien välittämään antiviraaliseen vasteeseen. Resistenssin murtamiseksi selvitettiin  
mahdollisuuksia käyttää turvallisesti hyväksi neurovirulentin SFV4 kannan 
voimakkaampaa replikaatiokykyä. Toisessa osatyössä SFV4:n neuropatogeneesiä pyrittiin 
heikentämään, estämällä sen kyky sitoa isäntäsolun amfifysiinejä viruksen ei-
rakenneproteiini 3:een tehdyn deleetion avulla. Kohdennettua replikaation estoa 
neuroneissa ei kuitenkaan saavutettu. Kolmannessa osatyössä SFV4:n kyky replikoitua 
neuroneissa pystyttiin kohdennetusti estämään lisäämällä viruksen genomiin 
kohdesekvenssejä neuroneissa ilmentyvää mikroRNA-124:ä vastaan (SFV4-miRT124). 
Neljännessä osatyössä selvitettiin SFV4-miRT124-viruksen hoitotehoa hiiren 
immunokompetentissa CT-2A glioomamallissa. Huomionarvoista oli että sekä SFV4 että 
muokattu SFV4-miRT124 kykenivät replikoitumaan glioomasoluissa tyypin I 
Interferonivasteesta huolimatta. Tämä hyödyllinen ominaisuus paransi SFV4-miRT124 
viruksen hoitotehoa CT-2A glioomia vastaan. 
Yhteenvetona voidaan todeta että viroterapian tehoa hiiren glioomamallissa pystyttiin 
lisäämään valjastamalla SFV4 viruksen kyky vastustaa tyypin I interferonivastetta 
kasvainsoluissa. Tulokset tukevat uusien onkolyyttisten alfavirusten kehitystyötä kliinisiä 
kokeita varten 
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Ago argonaute protein 
BAR Bin–Amphiphysin–Rvs domain 
BBB blood-brain barrier  
Bcl2L12 Bcl-2-like protein 12  
CAR coxsackievirus and adenovirus 
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signaling protein 
M-CSF  colony-stimulating factor  
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MHC major histocompatibility 
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miRNA microRNA 
MYXV myxoma virus 
NK natural killer cell 
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PDGFA  platelet-derived growth factor 
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pi. post infection 
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VEGF vascular endothelial growth 
factor 
VSV vesicular stomatitis virus 
VV vaccinia virus 
WEEV Western equine encephalitis 
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 1 Introduction 
Malignant gliomas are devastating tumors of the brain. Of these, glioblastoma (GBM) is the 
most frequent and most severe type of primary brain tumor (Crocetti et al., 2012; Furnari et 
al., 2007). GBM is associated with strong immunosuppression, proliferation, invasiveness 
and recurrence after therapy. The current standard care for malignant gliomas is maximal 
resection combined with radiation therapy and chemotherapy with alkylating agent 
temozolimide (Furnari et al., 2007). Despite therapy, malignant gliomas are always lethal. 
For glioblastomas, the median survival time is only 15 months (Stupp et al., 2005). Thus, 
there is an urgent need for novel effective therapies. Among the most promising new 
therapeutic approaches is oncolytic virotherapy which is based on tumor targeted and 
replication competent viruses leading to cancer cell lysis and potent priming of antitumoral 
immune responses (Chiocca and Rabkin, 2014; Lichty et al., 2014; Workenhe and Mossman, 
2014). 
Although oncolytic virotherapy against malignant gliomas has shown encouraging 
results in some of the patients in clinical trials, the overall evidence of therapy efficacy is 
still lacking. This outcome could be explained by host antiviral responses and premature 
clearance of the therapeutic virus. In addition, many currently used oncolytic viruses 
contain genetic modifications, which attenuate viral replication potency in the presence of 
functional cell autonomous type I interferon mediated antiviral signaling (Wollmann et al., 
2012). This inhibits viral spread in the healthy tissue and improves safety profile in patients, 
but likewise it can also potently hamper the spread of the virus where it is wanted, i.e. in 
the glioma tissue. Therefore, a new generation of viruses capable of more potent but 
targeted replication should be developed. 
Semliki Forest virus (SFV) is a positive strand RNA virus within the alphavirus family. 
Systemically administered, attenuated SFV vector VA7 has been shown to reach and 
destroy glioma xenografts in an immunocompromised mouse model (Heikkilä et al., 2010), 
warranting further studies. However, in order to evaluate the full oncolytic potency, further 
testing of VA7 is needed in immunocompetent glioma models which reconstitute the full 
interplay between the virus and the host immune system. Several SFV strains exist which 
display different neurovirulence properties in mouse models. Intriguingly, neurovirulent 
alphavirus phenotype has been associated with type I interferon (IFN) resistant replication 
potency (Deuber and Pavlovic, 2007; Simmons et al., 2010; Yin et al., 2009). However, taking 
advantage of the replicative power of virulent SFV against immunocompetent glioma 
requires neuron-specific attenuation strategies. In addition, a better understanding of 
molecular mechanisms behind the virulent phenotype is clearly required. 
This dissertation focuses on (I) host factors contributing to the failure or success of 
alphavirus based virotherapy in immunocompetent mouse glioma models; (II) on SFV 
neurovirulence; (II and III) strategies to specifically attenuate SFV replication and; (IV) the 
effects of SFV neurovirulence factors which promote glioma oncolysis. 
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2 Literature review 
2.1 MALIGNANT GLIOMA 
Glioma refers to a heterogeneous group of tumors of the neuroepithelial tissue. Gliomas 
share similar histological features with normal glial cells, but their exact etiology is not 
clear. The possible origin could be transformed normal glial cells, neural stem cells or 
oligodendrocyte precursor cells (Goffart et al., 2013). Based on their histopathological 
features, gliomas can be classified into astrocytoma, oligodendroglioma, oligoastrocytoma 
and ependymoma (Louis et al., 2007). They are divided into grades I - IV (World Health 
organization [WHO] grading system), where higher grade relates to increased malignancy. 
Malignant glioma, anaplastic astrocytoma and glioblastoma (GBM), representing WHO 
grades III and IV, are the most common types of primary intracranial brain tumors in 
adults (Crocetti et al., 2012; Furnari et al., 2007) and display high invasiveness and 
recurrence despite therapy. 
GBM (grade IV) is the most severe type of malignant glioma. It can arise via a 
progressive pathway from lower grade astrocytoma (secondary GBM) or as de novo primary 
GBM. Primary glioblastomas, typically diagnosed at later age (>45 years), account for 90% 
of the cases (Wen and Kesari, 2008). The standard treatment of GBM includes resection of 
tumor (if accessible) followed by radiation and chemotherapy. However, with the currently 
available therapy glioblastomas remain 100% fatal with median survival of patients for 
only 12 - 15 months (Stupp et al., 2005; Wen and Kesari, 2008). Consequently, there is an 
urgent need for novel effective therapies.  
Therapy resistance and recurrence of GBM can be associated with the presence of stem 
cell-like glioma initiating cells (GICs), which are capable of proliferation, self-renewal and 
multi-lineage differentiation (Tabatabai and Weller, 2011). Further characterization of such 
a cell population from GBM samples has revealed that GIC differentiation into glioma cells 
is associated with the expression of extracellular matrix components and integrins, creating 
a “differentiation niche” that facilitates GBM development (Niibori-Nambu et al., 2013). 
Interestingly, human cytomegalovirus (HCMV) DNA sequences and expression of viral 
genes have been found in the majority (if not all) of malignant gliomas (Dziurzynski et al., 
2012). As HCMV biology overlaps with cellular alterations classified as hallmarks of cancer, 
it has been concluded that HCMV can function as an oncomodulator in GBM (Dziurzynski 
et al., 2012). Although associated with GBM, there is no clear evidence of HCMV acting 
directly as a gliomagenic virus. Of note, HCMV seroprevalance is high (up to 80%), while 
the prevalence of glioblastoma is low (0.0257%; Dziurzynski et al., 2012). It is therefore 
likely that HCMV infects cells that have already gained alterations favoring cellular 
transformation. However, HCMV shows tropism towards neural progenitor cells, inducing 
abnormal and premature differentiation (Luo et al., 2010). This would also be indicative of 
HCMV glioma-inducing potential. 
2.1.2 Molecular pathology of malignant glioma 
GBMs are highly cellular neoplasms that are histologically characterized by a necrotic 
central area that is surrounded by pseudo-palisading rim of viable tumor cells that are 
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highly invasive. GBM cell invasiveness can be related to the hypoxic microenvironment in 
the tumor tissue that drives tumor cells to seek new viable ground to live on. Hypoxia also 
induces expression of hypoxia-inducible factor 1 (HIF-1) and pro-agiogenic factors such as 
vascular endothelial growth factor (VEGF) and interleukin 8 (IL-8) (Rong et al., 2006). 
Notably, malignant gliomas display a large amount of newly formed blood vessels that are 
highly permeable. At later stages the neovascularization disrupts the normal vessel 
structure causing blood-brain barrier fragility (Dubois et al., 2014).  
Commonly found oncogenic alterations in GBM include upregulated expression of 
epidermal growth factor receptor (EGFR), VEGF, murine double minute 2 (MDM2), 
platelet-derived growth factor subunit A (PDGFA), platelet-derived growth factor receptors 
(PDGFR), cyclin-dependent kinase (CDK) 4/6, Bcl-2-like protein 12 (Bcl2L12) and 
phosphoinositide 3-kinase (PI3K); inactivating mutations in p53, retinoblastoma protein 
(Rb) and phosphatase and tensin homolog (PTEN); loss of cyclin-dependent kinase 
inhibitor 2A (CDKN2A) and DCC; as well as loss of heterozygosity on choromosomes 10p, 
10q, 11p, 17p and 19q (Furnari et al., 2007; Louis, 2006; Walker et al., 2011; Wen and Kesari, 
2008). Of note, vast heterogeneity in gene expression between different glioblastoma 
subtypes and also among the cells of an individual tumor has been observed (Doucette et 
al., 2013; Patel et al., 2014; Sottoriva et al., 2013). 
Infiltration of both myeloid and lymphoid cells can be witnessed in gliomas. 
Importantly, the cytokine milieu of the glioma microenvironment has been shown to 
strongly skew the immune responses toward Th2 phenotype thus promoting immune 
tolerance. Indeed, although cytotoxic Th1 effector T cells (CD8+ T cells) are found in 
gliomas they have been shown to be unable to lyse glioma cells (Rolle et al., 2012).  
Glioma-associated microglia and macrophages (GAMs) recruited by the glioma cells 
have been shown to constitute a major fraction of the cells present in the glioma tissue 
(Badie and Schartner, 2000). The glioma microenvironment, however, polarizes GAMs 
towards M2 phenotype that mediates a number of immunosuppressive properties. These 
include: T-cell anergy via reduced expression of T cell activating ligands CD40, CD80 and 
CD86; induction of regulatory T cells (Tregs) via expression of interleukin 10 (IL-10) and 
tumor growth factor-β, (TGF-β) and; T-cell apoptosis via expression of Fas ligand 
(Wurdinger et al., 2014). Factors secreted by GAMs (such as matrix proteases) are also 
implicated in potentiating the invasiveness of glioma cells to surrounding healthy tissue 
(Coniglio and Segall, 2013). Indeed, accumulation of M2 phenotype GAMs correlates 
positively with increasing glioma grade (Prosniak et al., 2013). Notably, GICs have been 
shown to effectively recruit GAMs by expressing  chemokines such as macrophage colony-
stimulating factor (M-CSF) and (C-C motif) ligand 2 (CCL2) (Wu et al., 2010; Yi et al., 2011), 
thus providing additional linkage between the presence of GICs and the increased severity 
of gliomas.  
In addition to GAMs, Tregs play an important immunoregulatory role in malignant 
gliomas by inhibiting the activity of antigen presenting cells, natural killer (NK) cells and 
CD8+ T cells (Ooi et al., 2014). A key signaling hub in Treg induction seems to be signal 
transducer and activator of transcription 3 (STAT3). In glioma cells STAT3 (activated by 
hypoxia and cytokines) drives the expression of factors such as IL-10, prostaglandin E2, 
HIF-1 and TGF-β, which induce Treg recruitment and glioma cell survival. These factors 
activate STAT3 in glioma-associated immune cells, including macrophages and Tregs, thus 
creating a vicious immunosuppressive feedback loop (Ooi et al., 2014). In agreement with 
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their immunosuppressive characteristics, the amount of Tregs in the tumor correlates 
positively with glioma grade (El Andaloussi and Lesniak, 2007; Jacobs et al., 2010). Notably, 
increased populations of Tregs have been observed in human GBM samples, despite a 
decrease in total T cell count (Fecci et al., 2006). 
Analysis of major histocompatibility complex (MHC) expression has revealed a frequent 
loss of MHC class I (MHC-I) antigens (or HLA, human leukocyte antigen), in human GBM 
samples (Rolle et al., 2012). This together with high expression levels of HLA-E 
(Mittelbronn et al., 2007), a nonclassical MHC-I acting as a ligand for CD8+ and NK cell 
inhibitory receptor CD94/NKG2A, contributes to impaired cytotoxic activity of NK and 
CD8+ cells. Additionally, modulation of ECM components leading to obstructed T cell 
contacts with glioma cells, and induction of T cell apoptosis via expression of Fas ligand, 
CD70 and gangliosides, have all been observed in malignant gliomas (Rolle et al., 2012).  
Taken together, malignant gliomas harbor a plethora of oncogenic transformations 
through which they break free from the host tumor suppressive mechanisms. By default the 
central nervous system is not immunoprivileged but rather a tightly immunocontrolled 
region, where destructive cytotoxic Th1 responses are avoided. Malignant gliomas take 
advantage of this, inducing an even more Th2 skewed immune milieu promoting 
immunotolerance towards cancer cells. This, together with aggressive proliferation, 
hypoxia/GAM-driven invasiveness into healthy brain tissue (making complete tumor 
resection virtually impossible), and the presence of self-renewing stem cell like GICs, make 
malignant glioma a difficult malignancy to treat using conventional therapy.  
2.2 ONCOLYTIC VIROTHERAPY 
Oncolytic virotherapy refers to the use of replicating viruses to kill cancer cells. The 
notion of cancer remission in patients suffering from natural viral infections dates back to 
as far as the mid-1800s (Dey et al., 2013; Kelly and Russell, 2007). In the 1950s, the rise of 
modern virological techniques led to the treatment of patients with the first generation of 
oncolytic viruses (Dey et al., 2013; Kelly and Russell, 2007). Since then, multiple different 
viruses, including adenovirus, vaccinia virus, reovirus, Newcastle disease virus (NDV) and 
herpes simplex virus (HSV) have been studied for their antitumor effects. Indeed, oncolytic 
virotherapy has been emerging as a promising candidate therapy against malignancies 
resistant to standard cancer treatment.  
Despite encouraging results in animal models, the oncolytic virotherapy research field is 
still awaiting its first big success in clinical trials. To date there is only one accepted 
oncolytic virotherapy product on the market: Oncorine, a chimeric type 2/5 adenovirus 
with a partial deletion in E1B gene that has been approved in China as therapy for head 
and neck cancer (Ma et al., 2008). In addition, modified HSV (talimogene laherparepvec or 
Tvec, Amgen) has completed phase III trials for the treatment of melanoma 
(ClinicalTrials.gov Identifier: NCT00769704) where it showed therapeutic benefit 
(Andtbacka et al., 2013). 
The center of oncolytic virotherapy paradigm is cancer cell-specific replication of the 
virus, leading to lytic destruction of tumors. During the past decade this basic concept of 
oncolytic virotherapy has however moved from direct oncolysis to a more sophisticated, 
antitumor immune response-mediated model. It is today appreciated that detailed 
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understanding of the complex cross-talk between the host immune system, virus and the 
tumor is needed in order to push forward the development of novel effective oncolytic 
agents. The basic concepts and obstacles of oncolytic virotherapy are described in the next 
chapters. 
2.2.1 Mechanisms of action 
In the classical view, oncolytic viruses destroy cancer cells by viral replication caused 
lysis. Although complete tumor lysis can be seen in preclinical models, the rare successes in 
human trials have been associated with activated antitumoral immune responses. This, 
together with supportive results from preclinical animal models, has led to the maturation 
of the classical oncolytic virotherapy model to a modern concept of oncolytic 
immunovirotherapy or oncolytic vaccines. In this model, viral replication in cancer cells, in 
combination with cell lysis, promotes adaptive anti-tumor immune responses against the 
tumor (Chiocca and Rabkin, 2014; Melcher et al., 2011; Woller et al., 2014; Workenhe and 
Mossman, 2014). 
Oncolytic viruses provoke immune reactivity against the tumor tissue by replication-
induced immunogenic cell death (ICD). Such death mechanisms include immunogenic 
apoptosis, necrosis or necroptosis and pyroptosis. These  are characterized by the exposure 
of cytoplasmic damage-associated molecular pattern molecules (DAMPs) such as 
calreticulin, extracellular ATP, HMGB1 (high-mobility group box 1), heat shock proteins 
and uric acid (Guo et al., 2014). DAMPs act as recruiting and activating signals to antigen 
presenting cells, such as dendritic cells (DC), promoting cross-priming of antitumor CD8+ 
cells. This is in contrast to the classical form of apoptotic cell death, in which the retained 
plasma membrane integrity and formation of apoptotic bodies inhibit immune responses 
against the dying cells. It has become widely appreciated that virus-induced ICD can be 
used to break immune tolerance towards the tumor. In addition to direct lysis and ICD, 
viruses such as vesicular stomatitis virus (VSV) have been shown to target cells of the 
tumor vasculature, causing growth-inhibiting loss of blood flow in the tumor (Breitbach et 
al., 2011). Oncolytic virotherapy-induced antitumor mechanisms are shown schematically 
in Figure 1. 
A variety of oncolytic viruses expressing different therapeutic transgenes, such as tumor 
suppressor genes, prodrug-converting enzymes, antiangiogenic and immunostimulatory 
genes, have been developed in order to further improve the antitumor efficacy. These 
“armed viruses” can be utilized in tumor targeted delivery of a therapeutic genetic payload 
with putative synergistic effects of virus-mediated oncolysis. In particular, viruses armed 
with immunomodulatory cytokines, such as granulocyte macrophage colony stimulating 
factor (GM-CSF) have been utilized in order to further stimulate antitumor immune 
responses (Cerullo et al., 2010; Grossardt et al., 2013). Indeed, injection of GM-CSF 
expressing vaccinia virus into melanoma deposits, was found to induce infiltration of CD8+ 
cells also in noninjected metastases devoid of viral mRNA (Mastrangelo et al., 1999). Virus 
vectors expressing tumor-associated antigens (TAAs) have also been engineered. In fact, 
such viruses have been shown to induce adaptive immune reaction against the expressed 
TAAs even when infecting tissues other than the tumor (Granot et al., 2014). Such approach 
could thereby eliminate the need for replication in cancer cells.  
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Figure 1. Antitumor responses in oncolytic virotherapy. Oncolytic virus replication in the tumor 
cells causes immunogenic cell death and lysis of the cells resulting in the release of danger 
associated molecular patterns (DAMPs) and secretion of inflammatory cytokines (such as type I 
IFN) that potently activate antigen presenting cells (APC). APCs take up the released tumor-
associated antigens and cross-present them to naïve CD8+ T cells provoking their activation 
and antitumor effect. (M. Martikainen) 
2.2.2 Host antiviral responses limiting the efficacy of oncolytic virotherapy 
Despite advances in our understanding of the immune-mediated antitumor mechanisms, 
the central paradigm of oncolytic virotherapy remains: for effective therapy, oncolytic virus 
must first reach the tumor, then infect and spread efficiently in the tumor tissue. For this to 
take place, the virus has to overcome the antiviral defense of the host.  
Invading viruses are first recognized by host innate immune cells. These include NK 
cells, neutrophils, macrophages and DCs that are recruited to the site of infection to 
mediate clearance of infected cells (Brandstadter and Yang, 2011; Drescher and Bai, 2013). 
Subsequently, immune cells capable of antigen presentation migrate to draining lymph 
nodes, and present the viral antigens to naïve T cells. Of particular importance to the 
eradication of infected cells is DC-mediated priming of the cytotoxic CD8+ T cell response 
(Rouse and Sehrawat, 2010). DCs can prime CD8+ cells by presenting viral antigens via the 
MHC class I pathway after being infected by the virus, i.e. by endogenous expression of 
viral antigens. In another mechanism called cross-presentation, viral antigens from other 
infected cells (exogenous antigens) are taken up by the recruited DCs and presented on the 
MHC class I molecules (as opposed to typical MHC class II-restricted presentation of 
exogenous antigens), leading to cross-priming of CD8+ cells (Heath and Carbone, 2001). 
Although potently activated to recognize viral antigens, CD8+ T cells could also become 
cross-primed against host cell antigens engulfed by the DCs. Indeed, virus infection can 
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induce CD8+ cell-mediated experimental autoimmune encephalitis (Tsunoda et al., 2005), 
as well as antitumor CD8+ responses (as discussed later). However, the balance between 
therapy hampering (antiviral) and promoting (antitumor) responses is often tilted towards 
the antiviral effect, and thus contributing mainly to virus clearance. 
Presentation of viral antigens by APCs also stimulates B-cell mediated production of 
virus specific neutralizing antibodies. Indeed, even low titers of serum antiviral antibodies 
can greatly reduce the potency of intravenously administered oncolytic viruses. Thus, 
repeated systemic administration of the virus, or administration of a virus previously 
encountered by the patient’s immune system, can prove ineffective. This can be overcome 
to some extent by administering the virus directly into the tumor or as immunosuppressive 
combination therapy, e.g. together with cyclophosphamide (CPA) (Peng et al., 2013). In 
addition, coating the virus surface with biocompatible polymers or delivering the virus 
inside carrier cells could be used to circumvent peripheral neutralization of the virus 
(Russell et al., 2012). 
In addition to the peripheral antiviral interference, the tumor microenvironment can be a 
very hostile milieu for the entering virus. Inhibitory physical properties of tumor tissue 
such as dense extracellular matrix, interstitial fluid pressure, hypoxia and areas of necrosis 
can limit virus spread in the tumor tissue (Vähä-Koskela and Hinkkanen, 2014).  
2.2.3 Antiviral type I interferon response  
Type I IFN -mediated signaling is part of the cellular autonomous innate immunity, 
capable of effectively inhibiting virus replication. The mammalian type I IFN subtypes are 
designated IFN-α (13 subtypes in human), IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and 
IFN-ζ (also known as limitin). Of these IFN-α and IFN-β are the best characterized. They 
can be secreted by all nucleated cells in response to viral or bacterial infection.  
The initial cellular recognition of foreign invaders by sensing the pathogen-associated 
molecular patterns (PAMPs), such as viral nucleic acids, is orchestrated by the host cell 
pattern recognition receptors (PRRs). These include the Toll-like receptors (TLRs) which are 
found in the plasma membrane and endosomes, as well as the RIG-I like receptors (RLRs) 
which reside in the cytoplasm. The main detectors of viral nucleic acids include TLR9, 
TLR3, TLR7/8 and RLRs RIG-I and MDA5 (Mogensen, 2009). TLR9, TLR3 and TLR7/8 
recognize viral CpG DNA, dsRNA and ssRNA, respectively. RNA helicases, RIG-I and 
MDA5, detect structural features of viral dsRNA (Berke et al., 2013; Loo et al., 2008). Once 
activated, they trigger downstream antiviral signaling through a shared adaptor complex, 
the mitochondrial antiviral signaling (MAVS) leading to activation of transcription factors 
IRF3, IRF7 and NF-κB. These translocate into the nucleus where they drive the expression 
of type I IFNs as well as other proinflammatory cytokines. Recent findings suggest that 
RLR signaling can also induce apoptosis by activating caspase 8 via unique MAVS/caspase-
8 signaling complex (El Maadidi et al., 2014). Pathways involved in viral dsRNA-triggered 
type I IFN response are depicted in Figure 2. 
Type I IFNs secreted by the infected cells induce an antiviral state in the surrounding 
cell/tissue in autocrine, paracrine and endocrine fashion, by signaling through the 
JAK/STAT pathway (Ivashkiv and Donlin, 2014). The classical signaling pathway is 
activated by binding of the type I IFNs to the heterodimeric IFNα/β-receptors 
(IFNAR1/IFNAR2), leading to phosphorylation of receptor-associated Janus kinase 1 (JAK1) 
and tyrosine kinase 2 (TYK2). These in turn phosphorylate signal transducer and activator 
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of transcription (STAT) 1 and 2 that form the transcription factor ISGF3 together with IRF9 
(Figure 2). Once translocated into to nucleus, ISGF3 binds to genomic interferon-
stimulated-response-element (ISRE) promoter region and drives the expression of a 
number of IFN-stimulated genes (ISG) with antiviral effector function.  
From the wide range of different type I IFN subtypes, IFN-β seems to play a master 
regulator role at the onset of the antiviral response. It is produced as an early response 
(followed by IFN-α4) by the infected cell, and primes the neighboring cell for incoming 
virus attack (Lienenklaus et al., 2008). Cells in such a primed state can then rapidly respond 
to virus infection by production of late type I interferons (i.e. different IFN-α subspecies). In 
fact, mounting a complete antiviral response requires both the priming signal by type I 
interferons and subsequent recognition of the virus by PRRs (Kuri et al., 2009). 
 
Figure 2. Induction of type I IFN and type I IFN mediated signaling. Viral dsRNA, ssRNA and 
CpG DNA are recognized by host cell PRRs leading to the induction of type I IFN and 
proinflammatory cytokines. In addition, recognition of viral dsRNA by RLRs (RIG-I, MDA5) or 
PKR leads to induction of apoptosis or inhibition of translation, respectively. Type I IFN 
mediated signaling via IFN receptors (IFNAR1/2) leads to phosphorylation of STAT1 and STAT2 
which together with IRF9 form the transcription factor ISGF3 that drives the expression of 
antiviral interferon stimulated genes (ISGs). (M. Martikainen) 
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inhibiting the JAK/STAT pathway (Brzózka et al., 2007). Resistance of the virus to antiviral 
responses is often associated with increased spread and pathogenicity. The majority of 
viruses utilized in clinical trials are therefore often engineered or selected to display 
sensitivity to type I IFNs by mutation or deletion of their virulence genes. The rationale for 
the use of such viruses is interferon signaling deficiencies in tumors (Critchley-Thorne et 
al., 2009; Stojdl et al., 2000), which allow virus replication in cancer cells while healthy cells 
are protected. Such deficiencies can rise e.g. from commonly found overactivating 
mutations of the RAS/Raf1/MEK/ERK signaling pathway that suppresses transcription of 
type I IFN inducible genes (Christian et al., 2012).  
Notably, virus replication-induced expression of type I IFN has also been shown to act as 
DAMP, enhancing DC maturation and cross-priming of CD8+ T cells (Diamond et al., 2011; 
Garcin et al., 2013; Schiavoni et al., 2013). In fact, mice deficient of IFNAR1 in their DCs 
have been shown to be unable to mount effective CD8+ responses against immunogenic 
tumors (Diamond et al., 2011). Interestingly, in a mouse B16 melanoma model, inhibition of 
host competence to produce type I IFN boosted VSV replication in the tumor, but also led 
to impaired antitumor efficacy (Wongthida et al., 2011). This was possibly due to impaired 
recruitment of immune cells to the site of infection. Thus, type I IFN signaling has a 
complex role in the cross-talk between the virus, cancer cells and the immune system, 
having not only an anti-oncolytic but possibly also a therapy enhancing role.  
2.3 ONCOLYTIC VIROTHERAPY OF MALIGNANT GLIOMA 
One of the earliest preclinical reports of oncolytic virus used against human glioblastoma 
model was published by Martuza et al. (1991). Since then many viruses have been 
harnessed and some have reached phase I/II clinical trials (presented in table 1).  
In the majority of therapy trials, the virus has been administered directly into the tumor 
or into the resection cavity after surgical removal of the glioma tissue. As for now, clinical 
trials employing the viruses described above have primarily focused on safety and dose 
escalation aspects (phase I/II). In this respect, the trials can be considered successful as the 
viruses used in these studies have proved safe, reporting almost complete lack of adverse 
events (Koks et al., 2015b). This is in drastic contrast to conventional radiation therapy and 
chemotherapy that have shown significant toxic side effects. However, the success in 
virotherapy has been limited to only a few (if any) patients per trial (Koks et al., 2015b; 
Wollmann et al., 2012).  
In addition to viruses that have already been evaluated in clinical settings, many others 
have been extensively studied in animal models. However, evaluation of the oncolytic 
potency has often been conducted by using human glioma xenograft models. Translation of 
such results into clinics might become problematic due to restricted immune reactivity. 
Therefore, preclinical studies carried out in syngeneic models are of the utmost importance. 
The list of viruses that have shown therapeutic potency in immunocompetent rodent 
glioma models but have not yet entered clinical trials includes myxoma virus (MYXV) 
(Zemp et al., 2014), vaccinia virus (Lun et al., 2010a) and VSV (Alain et al., 2010).  
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Table 1. Oncolytic virotherapy trials against glioma. Source: ClinicalTrials.gov, U.S. National 
Institutes of Health (https://clinicaltrials.gov). 
Therapy Status (last updated) Identifier Phase 
PVS-RIPO (engineered poliovirus) Recruiting (2015) NCT01491893 I 
Adenovirus DNX-2401 and IFN-gamma Recruiting (2015) NCT02197169 I 
Measles Virus Producing CEA (MV-CEA) Recruiting (2014) NCT00390299 I 
HSV-1 Expressing IL-12 (M032) Recruiting (2014) NCT02062827 I 
HSV-1716 and dexamethasone Recruiting (2014) NCT02031965 I 
Adenovirus DNX2401 and Temozolomide Recruiting (2014) NCT01956734 I 
Toca 511 (retroviral replicating vector) Recruiting (2014) NCT01985256 I 
Toca 511 and 5-FC Recruiting (2014) NCT01156584 I/II 
Adenovirus DNX-2401 Ongoing (2014) NCT00805376 I 
Adenovirus  
(Ad-hCMV-TK and Ad-hCMV-Flt3L) 
 
Recruiting (2013) NCT01811992 I 
ParvOryx (parvovirus H-1) Recruiting (2013) NCT01301430 I/II 
Adenovirus DNX-2401 Unknown (2012) NCT01582516 I/II 
Toca 511 Recruiting (2012) NCT01470794 I 
Adenovirus DNX-2401 Unknown (2012) NCT01582516 I/II 
NDV-HUJ (Newcastle disease virus) Unknown (2010) NCT01174537 I/II 
Reolysin (Reovirus) Completed (2010) NCT00528684 I 
HSV-G207 and radiation therapy Completed (2008) NCT00157703 I 
HSV-G207 Completed (2003) NCT00028158 I/II 
2.3.1 Host responses contributing to the efficacy of antiglioma oncolytic virotherapy 
The evident discrepancy between encouraging preclinical results and poor clinical 
efficacy calls for detailed evaluation of factors contributing to both the failure and success 
of oncolytic virotherapy. It is widely accepted that the interplay between virus, cancer cells 
and immune system dictates the outcome of the therapy. Due to the early phase of the 
current clinical trials, information concerning the immunological aspects of treated patients 
is limited. However, there has been observation of GBM infiltrating CD8+ cells, monocytes 
and macrophages in some patients following oncolytic intratumoral administration of HSV 
(G207) (Markert et al., 2008).  
As noted before, glioma xenograft models lack adaptive immune components that have 
been shown to be crucial for the success of therapy. Indeed, in the study by Koks and 
colleagues (2015a), NDV-mediated destruction of syngeneic mouse GL261 gliomas was 
dependent on the induction of ICD and subsequent activation of antiglioma CD8+ T cells. 
Also injection of adenovirus (DNX-2401) into GL261 cells was shown to promote Th1 
antitumor immunity by inducing IFN-γ, upregulating MHC I expression and increasing 
CD8+ cell counts in the tumor microenvironment (Jiang et al., 2014). Notably, in these 
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studies, long-term survival was shown in a significant portion of the animals following 
intratumoral virus injection. In fact, NDV therapy mediated survival benefit was worse in 
glioma carrying immunodeficient Rag2-/- or in CD8+ depleted mice than in 
immunocompetent counterparts (Koks et al., 2015a). Similarly, GL261 mouse glioma cells 
preinfected with parvovirus (Minute virus of mice) showed reduced capability of glioma 
induction in immunocompetent mice while growing potently in immunodeficient animals 
(Grekova et al., 2012). Taken together, these clearly indicate that the oncolytic potency 
should be evaluated in immunocompetent animal models. Perhaps the most impressive 
result in immunocompetent glioma model has been achieved in the orthotopic rat RG2 
model following intravenous parvovirus H-1 injection. In this study by Geletneky et al. 
(2010), six out of nine treated glioma-bearing rats (virus administered intravenously on 8 
consecutive days) showed long-term response accompanied by resistance to RG2 
rechallenge even one year after being cured from the initial glioma. Although 
immunological aspects were not studied in detail, the existence of long-term antitumor 
immune memory must be due to strong adaptive immune stimulation. 
Viruses armed with immunostimulatory cytokine IL-12 have proven to be potent in 
immunocompetent glioma models (Cody et al., 2012; Markert et al., 2012; Roche et al., 
2010). Combined with virotherapy, expression of IL-12 from infected cells can induce the 
expression of multiple cytokines from IL-12 receptor expressing immune cells (T cells, 
macrophages and NK cells). The critical component of IL-12 mediated antitumoral effect is 
IFN-γ induction, which stimulates Th1 immunity (Roche et al., 2010). In addition, IL-12 
expression primes CD8+ cells (Th1 effector cells) and inhibits tumor angiogenesis 
(Trinchieri, 2003; Voest et al., 1995). Notably, the CD8+ priming effect of armed SFV 
encoded IL-12 was reported to be strongly dependent on vector-induced type I IFN 
expression, as tumor-specific CD8+ T-cell responses were impaired in IFNAR-defiecient 
mice (Melero et al., 2015). 
Another cytokine showing impressive results in in vivo glioma models is FMS-like 
tyrosine kinase 3 ligand (Flt3L), which stimulates differentiation of dendritic cells (Ali et al., 
2004). Studies with Flt3L expressing HSV G47Δ and adenovirus indicated that the potency 
of these therapies was associated with increased infiltration of DCs into glioma tissue. 
Infiltrated DCs in turn mediated strong tumor antigen presentation once activated by 
DAMPs released from dying glioma cells (Ali et al., 2004; Barnard et al., 2012). Both 
adenovirus expressing Flt3L and HSV expressing IL-12 are currently being tested in phase I 
clinical trials (Table 1). 
The immunosuppressive drug cyclophosphamide (CPA) has been shown to increase the 
infectivity and replication of HSV, MYXV and vaccinia virus in immunocompetent glioma 
models (Fulci et al., 2006; Lun et al., 2009; Zemp et al., 2014). The mechanisms behind this 
effect seem to involve inhibition of monocyte infiltration into glioma tissue in response to 
virotherapy. In the case of HSV, CPA was shown to potentiate viral replication by 
inhibiting stromal expression of IFN-γ (Fulci et al., 2006). One source of stromal IFN-γ is 
NK cells that can help in eradication of infected tumor cells. However, NK cells infiltrating 
into the infected glioma tissue were found to mediate obstruction of HSV therapy rather 
than potentiate the responses in both immunodeficient and immunocompetent mouse 
glioma models (Alvarez-Breckenridge et al., 2012). Similarly, depletion of NK cells 
(combined with ablation of T cells within the tumor) improved the persistence of oncolytic 
myxoma virus in immunocompetent mouse glioma model (Zemp et al., 2014). 
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As discussed in chapter 2.1.2, glioma cells harbor oncogenic alterations that mediate their 
survival and spread in the hypoxic microenvironment. Indeed, glioma cells show increased 
resistance to reactive oxygen species and apoptosis induced by endoplasmic reticulum (ER) 
stress (Fathallah-Shaykh, 2005). As shown by Koks et al. (2015a), NDV induced CD8+ T cell 
priming against syngeneic GL261 cells via induction of necroptosis and autophagy. 
Meanwhile parvovirus H-1 effectively killed human malignant glioma cells that were 
resistant to genotoxic stress and apoptosis (Di Piazza et al., 2007). These results indicate that 
oncolytic virotherapy can be effective also in cancer cells resistant to apoptosis.  
At least some glioblastomas have functional type I IFN signaling. Malignant human 
glioma samples analyzed by Alain et al. (2010) were able to respond to and produce type I 
IFN. Thus, virus replication in the glioma periphery and/or stroma can promote strong 
antiviral response in the tumor tissue. More detailed analysis of human glioblastoma 
samples has revealed variable levels of type I IFN activity, ranging from elevated to absent 
(Cosset et al., 2014; Duarte et al., 2012). This would indicate that, although considered the 
“Achilles heel” of cancer cells, defective type I IFN signaling cannot be taken for granted in 
GBM. Indeed, inhibition of systemic type I IFN production in plasmacytoid dendritic cells 
with mTORC inhibitory drug rapamycin has been shown to increase virus replication in the 
tumor and prolong survival of RG2 glioma-bearing rats when given in combination with 
vesicular stomatitis virus (VSVΔM51) (Alain et al., 2010) or GM-CSF expressing vaccinia 
virus (JX-594) (Lun et al., 2010a).  
In an ideal case, oncolytic virotherapy could be utilized to destroy the highly 
immunosuppressive microenvironment of gliomas. Consequently, the efficacy of 
virotherapy may be reduced in immunodeficient hosts (Grekova et al., 2012; Koks et al., 
2015a). Together with the attenuated replication profiles of clinically applied viruses, this 
could mean that immunosuppressed patients may not benefit from treatments using 
oncolytic virus. This is relevant when considering that lymphopenia has been observed in 
GBM patients treated with HSV in clinical trials (Koks et al., 2015b) and also because 
standard glioma therapy includes radiation and chemotherapeutic drugs, which  have 
immunosuppressive effects.  
To summarize, the key to successful glioma virotherapy seems to reside in modulating 
host immune responses in a manner that supports virus replication and spread in the 
glioma tissue (i.e. inhibiting antiviral immune responses) but simultaneously promoting 
antitumoral immunity. Potent virotherapy-mediated ICD of glioma cells followed by 
induced CD8+ T cell responses have been reported to be the main mechanism behind long-
term treatment effect (Barnard et al., 2012; Koks et al., 2015a). It must however be kept in 
mind that adaptive immune stimulation follows the effective virus replication and cell lysis 
in the tumor tissue. Thus, the ability to overcome innate, abortive responses, such as type I 
IFN response leading to premature virus clearance, in the glioma microenvironment is 
crucial for treatment efficacy.  
2.3.2 Targeting oncolytic virus to glioma 
A major aspect of designing oncolytic viral agents against gliomas and other tumors of 
the central nervous system (CNS) is the necessity for sufficient attenuation of hazardous 
replication in normal cells, especially neurons. Some strategies to achieve this goal are 
outlined in the following section. 
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Naturally occurring impairment of oncolytic viruses to replicate in healthy cells is in 
most occasions related to attenuated replication potency under innate, cell autonomous, 
antiviral signaling. As an example, the measles virus which has been used in clinical setting 
is derived from the type I IFN-sensitive Edmonston strain (Haralambieva et al., 2010). Also 
replication of Sabin strain of poliovirus, which was used as a backbone for PVS-RIPO, 
shows sensitivity to type I IFN (Lancaster and Pfeiffer, 2011). Similarly, oncolytic VSV 
(Stojdl et al., 2000), NDV (Krishnamurthy et al., 2006) and reovirus (reolysin) (Shmulevitz et 
al., 2010) preferentially replicate in type I IFN-defective cancer cells. In addition, H-1 
parvovirus (ParvOryx) is naturally sensitive to PKR-mediated antiviral response (Ventoso 
et al., 2010). 
Oncolytic HSVs used in clinical trials (HSV1716 and G207) are PKR-sensitive due to the 
engineered deletion of the HSV gene γ34.5, which encodes the ICP34.5 protein. ICP34.5 
mediates dephosphorylation eIF2α, thus allowing protein translation to continue despite 
PKR activation. Notably, γ34.5 is a major genetic factor contributing to HSV neurovirulence 
(Ning and Wakimoto, 2014). Hence, deletion of γ34.5 promotes safety by increasing the 
sensitivity of HSV to PKR activity and by inhibiting neuronal replication. Although safe, 
the γ34.5 deleted HSV have shown low efficacy against GBM in clinical phase I/II trials 
(Ning and Wakimoto, 2014). Indeed, the ability of HSV1716 and G207 to replicate is limited 
not only in healthy cells but also in cancer cells, and in human GICs as well (Wakimoto et 
al., 2009). Consequently new targeting strategies, such as receptor mediated targeting or 
partial preservation of the γ34.5 gene, have been evaluated but preclinical tests in 
immunocompetent models are still lacking (Ning and Wakimoto, 2014). Currently in phase 
I/II clinical trials is HSV G47Δ, a third generation oncolytic HSV with an additional deletion 
in the nonessential α47 gene. This modification induces early ectopic expression of viral 
US11 gene that precludes eIF2α phosphorylation, thereby enhancing virus replication. 
G47Δ has shown increased potency to infect human glioma cell lines and patient-derived 
GICs (Sgubin et al., 2012; Todo et al., 2001). Notably, increased MHC I expression and 
enhanced T cell stimulation has been observed in G47Δ-infected tumor cells (Todo et al., 
2001). This feature could possibly increase the efficacy of virotherapy by strengthening the 
adaptive immune reactivity against the tumor.  
The adenoviruses used in oncolytic virotherapy have targeted mutations in the E1A and 
E1B genes, and these mutations promote cancer cell specific replication. As an example, 
clinically used adenovirus DNX-2401 (formerly known as Delta-24-RGD-4C) has a deletion 
in the viral E1A protein Rb binding site, allowing replication only in glioma cells with 
impaired Rb function (Fueyo et al., 2000). DNX-2401 is based on adenovirus serotype 5 
(Ad5). Low expression of Coxsackie and adenovirus receptor (CAR), which is used by Ad5 
for entry, has been observed in human gliomas and could limit Ad5 infectivity. To 
overcome this, DNX-2401 carries an inserted RGD-4C peptide motif in the attachment 
mediating viral fiber, allowing attachment to cell surface integrins and improving 
infectivity in glioma cells (Fueyo et al., 2003). Other examples of glioma-specific targeting 
by modifying the viral surface molecules include the measles viruses that have been 
engineered by genetically fusing targeting molecules such as IL-13 or CD133-specific single-
chain antibody with viral glycoprotein. IL-13 and anti-CD133 present on the surface of the 
virus promote targeting to glioma cells (by binding to IL-13 receptor) or GICs (by binding 
to CD133) respectively (Allen et al., 2008; Bach et al., 2013). 
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Among the newest (and maybe the most promising) oncolytic virus candidates is PVS-
RIPO, a modified replicative poliovirus (Goetz and Gromeier, 2010), that recently entered 
clinical phase I trial (ClinicalTrials.gov identifier: NCT01491893). Poliovirus receptor 
Nectin-like molecule 5 (Necl-5), is highly expressed in malignant cells and in patient GBM 
samples (Merrill et al., 2004), thereby potentiating poliovirus infectivity in GBM. However, 
expression of Necl-5 also mediates infectivity in lower motor neurons causing serious 
neuropathogenicity. To overcome this, neuronal replication of PVS-RIPO is abolished by 
replacing the poliovirus internal ribosome entry site (IRES), which allows translation of 
uncapped (+)RNA virus genomes, with the human rhinovirus serotype 2 (HRV2) IRES site 
(Goetz and Gromeier, 2010). The same strategy has been used to inhibit neuronal 
replication of VSV, HSV and rabies virus (Ammayappan et al., 2013; Campbell et al., 2007; 
Marschalek et al., 2009). The exact mechanism behind the dysfunction of HRV2 IRES in 
neurons is not known but it is speculated to be associated with HRV2 IRES binding to 
neuronally expressed RNA-binding protein DRBP76:NF45 followed by inhibition of 
translation initation (Goetz and Gromeier, 2010). 
Alternative strategies to attenuate VSV neurovirulence include mutations in the matrix 
protein (counteracting the host immune system), insertion of neuron-specific microRNA 
target sequences, combination of VSV with trans-complementing propagation-deficient 
vectors and pseudotyping envelope glycoproteins with envelope proteins of other viruses 
(such as measles) (Ayala-Breton et al., 2012; Kelly et al., 2010; Muik et al., 2012, 2014). The 
targeting of oncolytic viruses by insertion of miRNA-specific sequences within the viral 
genome is discussed in more detail in chapter 2.5.2. 
2.4 SEMLIKI FOREST VIRUS AND OTHER ALPHAVIRUSES 
Alphaviruses are enveloped viruses with a positive-sense single stranded RNA genome 
(Group IV, family: Togaviridae). With the exeption of salmon alphavirus, they are spread 
by mosquitoes, and their natural hosts are small birds and mammals. However, some 
members of the alphavirus family are also capable of causing disease in humans. 
Alphaviruses are divided by geographical distribution and symptoms into arthitogenic Old 
World alphaviruses (e.g. Chikungunya virus [CHIKV] and sindbis virus [SINV]) and 
encephalitis-causing New World alphaviruses (such as Venezuelan equine encephalitis 
virus [VEEV]). 
Semliki Forest virus (SFV) is a prototype alphavirus found naturally in Africa. Only a 
few cases of SFV outbreaks in humans have been reported and they were associated with 
symptoms such as fever, headache, myalgia and fatique (Mathiot et al., 1990). Notably, one 
fatal infection of a laboratory worker, who was accidentally exposed to large amounts of 
virulent Osterrieth strain, has been reported (Willems et al., 1979). Despite these reports, 
SFV is generally not considered a potent human pathogen. Therefore, it is suitable as a 
model alphavirus for research (biosafety level 2). Schematic presentation of the alphavirus 
virion and genome structures is provided in Figure 3.  
SFV represents a novel candidate for antiglioma oncolytic virotherapy. This is evident 
from preclinical results gained in the human U87 glioma xenograft model, where single 
systemic injection with the virus caused complete eradication of orthotopic tumors 
(Heikkilä et al., 2010). In the earlier work, an initial delay in immunocompetent rat BT4C 
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glioma growth following intratumoral virus injection was observed (Määttä et al., 2007). 
The replication of SFV and alphaviruses in general, host responses and implications in 
oncolytic therapy are presented in the following chapters.  
 
 
 
Figure 3. Structure of the alphavirus virion and genome. The virion is enveloped, spherical, and 
65-70 nm in diameter. The capsid is made of 240 monomers. The envelope contains 80 trimers 
of E1/E2 proteins (spikes). The genome is capped and polyadenylated (+)ssRNA of 11-12 kb in 
length. The genome has open reading frames for nonstructural and structural polyproteins that 
are processed as indicated. Subgenomic RNA contains downstream hairpin loop (DLP) that 
allows translation despite PKR activation. Modified from ViralZone (www.expasy.org/viralzone, 
Swiss Institute of Bioinformatics) 
2.4.1 Entry and replication  
Alphaviruses bind to their target cells with viral spike, primarily with E2 glycoprotein, 
and enter via receptor-mediated endocytosis in clathrin-coated pits. The receptor needed 
for SFV entry is currently not known. In vitro SFV can infect a wide variety of different cell 
types, indicating that SFV can use multiple different receptors or that the receptor is a 
conserved molecule. Interestingly, both SFV and SINV have been shown to adapt during 
passaging in cell culture by increasing their capability to use glycosaminoglycan heparan 
sulfate as an attachment receptor (Klimstra et al., 1998; Smit et al., 2002). Also, a recent 
report by Ooi et al. (2013) indicated that depletion of Fuzzy homologue protein (conserved 
from mosquitoes to humans) inhibited SFV endocytosis, giving a clue to the proteins 
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needed for SFV entry. Interestingly, as opposed to the widely accepted entry by receptor 
mediated endocytosis, Vancini et al. (2013) suggested that, at least in conditions inhibiting 
endocytosis, alphavirus RNA could enter the cell directly through the plasma membrane 
via a pore generated by the virus and host proteins  
The mildly acidic environment in the maturating endosome triggers dissociation of the 
E1-E2 hetrodimer, revealing the E1 fusion loop. The E1 fusion-peptide is inserted into the 
endosomal membrane and it then trimerizes. This leads to mixing of viral and endosomal 
membranes and finally to formation of a pore that allows release of the capsid into the 
cytoplasm. Once released from the endosome, the virus capsid is uncoated by ribosomes 
(60S ribosomal subunit) and the virus genome is released into the cytoplasm (Jose et al., 
2009).  
In the cytoplasm, the 5’-capped and polyadenylated viral 42S RNA genome can be 
directly used as a template for transcription. The initial transcription product is a single 
nsP1234 polyprotein which is first processed into individual nsPs by nsP2 protease activity. 
First, nsP4 is cleaved from the polyprotein, forming a short-lived early replicase (P123 + P4) 
that copies viral 42S RNA to a complementary negative strand. Subsequent cleavage of 
P123 into P1 + P2 + P3 converts the replicase complex into a stable positive strand 
polymerase producing more 42S RNA genome (late replicase) (Jose et al., 2009; Vasiljeva et 
al., 2003).  In later stages of replication, processing of the nsP polyprotein also produces 
nsPs which are not associated with the viral replication complex (RC). In such form nsP1 
associates with cellular membranes, nsP2 translocates into the nucleus and nsP3 forms 
cytoplasmic aggregates (Jose et al., 2009; Vasiljeva et al., 2003).  
In the late phase the viral RC also produces subgenomic 26S RNA that encodes viral 
structural glycoproteins. These are also first translated into a single polyprotein C-pE2-6K-
E1. Capsid (C) is the first to be cleaved from this by autoproteolysis. Subsequently the 
remaining pE2-6K-E1 polyprotein is inserted into the ER and processed by host signal 
peptidase. Synthesized pE2 and E1 form heterodimers which are transported to the cell 
surface via the Golgi complex. In the Golgi lumen, pE2 precursor is further processed to 
form mature E2 and E3 by host furin-like protease. The earlier cleaved capsid proteins 
recognize and bind the newly synthesized viral (+)ssRNA and forms the nucleocapsid. At 
the plasma membrane, the capsid associates with the cytoplasmic domain of E2, thus 
driving the budding process. The nucleocapsid (containing the viral genome) is enveloped 
by the E1-E2 heterodimer-containing host plasma membrane and the newly formed virions 
are then released from the host cell (Jose et al., 2009; Leung et al., 2011). 
As with all (+)ssRNA viruses Alphavirus RNA replication associates with modified 
cellular membranes. In SFV-infected cells, the membrane spherules that contain the 
replication complex are first formed at the plasma membrane. These translocate later into 
the perinuclear region by trafficking that requires an intact actin-myosin network and PI3K-
activity (Spuul et al., 2010). Replication complex proteins are hypothesized to be located at 
the opening of the structure, where they synthesize new (+)RNA that is released into the 
cytoplasm. As the spherules are internalized they also fuse with acidic cell vesicles into 
large structures, named cytopathic vacuoles (CPV-I). It is believed that the evolutionary 
reason for spherule formation is to hide virus dsRNA replication intermediate from host 
cell RLRs, thus promoting the evasion from the antiviral response (Overby et al., 2010). 
Alphavirus replication cycle is presented in Figure 4. 
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Figure 4. Alphavirus replication cycle. 1: The virus enters by receptor-mediated endocytosis. 2: 
Capsid is released into the cytoplasm. 3: (+)ssRNA genome is uncoated and translated by 
ribosomes, the initial product being nsP polyprotein which is processed to individual nsPs. 4: 
Replication complex spherules form first at the plasma membrane and (5) are subsequently 
internalized.  Spehurels are eventually fused with other cellular vesicles finally forming large 
cytopathic vacuoles (CPV-I, 6). 7: Later during replication the virus replicase produces viral 
subgenomic RNA that is translated into the structural polyprotein. 8: The viral +ssRNA genome 
is encapsidated by capsid protein. 9: The viral envelope proteins are processed via the ER and 
Golgi and are finally translocated to the plasma membrane. 10: At the plasma membrane new 
capsids associate with envelope proteins forming new virions. At later stages of infection nsP2 
can be found in the nucleus and nsP3 in the cytoplasm as aggregates. (M. Martikainen.) 
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2.4.2 Alphavirus neuropathogenesis  
Due to the severe symptoms of some alphaviruses, such as CHIKV and VEEV, in humans, 
the associated disease mechanisms have been studied. Most of the studies have been 
conducted in mouse models, in which alphavirus pathogenicity manifests as severe 
encephalitis.  SFV and SINV have been widely utilized as model alphaviruses.   
Several different strains of SFV exist, exhibiting varying neuropathogenicity in mice. 
Strains such as L10 and SFV4, capable of replicating in neuronal cells of adult mice, are 
termed neurovirulent and originate from the first SFV isolate from Uganda (1942) 
(Smithburn et al., 1946). In contrast, some strains, such as A7(74), have attenuated capacity 
to infect neurons of adult mice. These are termed avirulent and they derive from the second 
SFV isolate form Mozambique (1959) (McIntosh et al., 1961). Importantly, both avirulent 
and neurovirulent SFV strains are lethal to suckling mice and are able to penetrate the CNS. 
This natural tropism in rodent models has led to a great interest to exploit this property to 
target CNS malignancies such as GBM. However, neuronal replication, associated 
especially with neurovirulent SFV strains, raises safety concerns. Therefore, the molecular 
mechanisms behind the neurovirulence need to be understood and taken into account in 
the development of targeted oncolytic SFV vectors.   
Upon systemic administration, SFV replicates in peripheral cells and causes serum 
viremia. The viremia lasts for 3-4 days before being cleared by antibodies. After the 
peripheral replication phase SFV finds its way to the CNS tissue (Atkins, 2013; Fazakerley, 
2002). There are srain-specific differences in the CNS penetration of alphaviruses. It can 
occur directly through the blood-brain barrier (BBB) or via the olfactory epithelium (Atkins 
2013; Gardner et al., 2008). In the case of SFV, entry into the CNS is considered to occur 
mainly through the BBB and it is associated with BBB breakdown and increased expression 
of intercellular adhesion molecule 1 (ICAM-1) followed by infiltration of neutrophils 
(Erälinna et al., 1996). In support of this, foci of infected cells can be seen around the blood 
vessels in the brain also after peripheral infection of attenuated SFV strains (Fazakerley et 
al., 1993). 
Even though both avirulent and virulent SFV strains show similar tropism toward the 
CNS, only virulent strains can continue to spread in the brain tissue and ultimately cause 
severe encephalitis. The robust replication of neurovirulent SFV is associated with 
expression of proinflammatory cytokines (Tuittila et al., 2004). Studies done with SINV 
indicated that infection in the brain induced CD8+ T cell infiltration which mediated 
clearance of the infected cells, and was later followed by CD4+ T cells and antibody-
producing B cells (Metcalf and Griffin, 2011). In a recent study it was shown that the 
pathogenicity of SINV-associated encephalitis in mice was in fact more related to CNS 
infiltration of Th1/Th17 T-cells than the virus infection itself  (Kulcsar et al., 2014). 
Among CNS cell types, oligodendrocytes and neurons seem to support SFV replication, 
whereas infection is rarely seen in astrocytes (Fragkoudis et al., 2009). Tropism toward 
oligodendrocytes in the corpus callosum can also be seen, when avirulent SFV, incapable of 
replicating in neurons, is injected directly into the brain (Fazakerley et al., 2006). A 
schematic picture of SFV pathogenesis in mice is presented in Figure 5. 
For the avirulent SFV strains the peak viremia in the CNS occurs 5-7 days post infection 
after which the virus is cleared by antibodies. Although neuronal damage is minimal, 
avirulent SFV infection causes temporal immune-mediated demyelination (Fazakerley and 
Webb, 1987a). This could be associated with oligodendrocyte infection and/or molecular 
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mimicry between myelin and viral proteins leading to autoimmune reaction. The mice 
however survive the infection and display only mild if any symptoms. Interestingly, the 
neurovirulence of avirulent SFV strains is age-dependent, which means that prominent 
neuronal infections can be witnessed in young mice, whereas virus spread in adult mouse 
neurons is attenuated (Atkins 2013; Fazakerley, 2002). 
The molecular mechanisms of age-dependent neurovirulence are still unknown but 
could be related to a switch from Th2 to Th1 cytokines (e.g. IFN-γ) during mouse CNS 
maturation (Lovett-Racke et al., 2000). Notably, IFN-γ has been shown to mediate neuronal 
noncytolytic clearance of SINV (Burdeinick-Kerr et al., 2009). Also, increased expression of 
antiviral type I IFN signaling pathway components, including IRF3, IRF7 and STAT1, has 
been shown in response to neuronal maturation (Farmer et al., 2013; Schultz et al., 2015). 
This would suggest that avirulent alphaviruses fail to replicate in mature neurons due to 
enhanced type I IFN responses.  
In general,  neurovirulence of alphaviruses can be associated with the ability to inhibit 
type I IFN mediated JAK/STAT-signaling in infected cells (discussed in more detail in 
chapter 2.4.3) (Simmons et al., 2010). However, studies conducted in IFNAR-1 deficient 
mice showed that type I IFN signaling is crucial in protecting peripheral organs and tissues 
but not the CNS from SFV infection (Fragkoudis et al., 2007). As indicated by Yin et al. 
(2009), increased neuronal replication potency of another alphavirus VEEV is more likely 
due to increased resistance to the pre-established antiviral state, i.e. the virus retains its 
replication capability despite active antiviral signaling rather than by inhibiting it. Analysis 
of neuron subtypes has also revealed that, in comparison to cortical neurons, granule 
neurons display upregulated basal levels of antiviral ISGs, such as STAT1, Ifit1, OAS and 
Mx1, and this correlates with reduced susceptibility to positive-strand RNA viruses (Cho et 
al., 2013). In addition, studies performed using mouse primary cortical neurons indicated 
that the cytoprotective response against Western equine encephalitis (WEEV) depended on 
the activation of IRF3 but not on the autocrine or paracrine activity of type I IFN (Peltier et 
al., 2013). Altogether, these findings imply that type I IFN expression is not needed to 
protect neuronal cells from alphavirus infection.  
Although capable of replicating in the presence of type I IFN stimulus in vitro, infection 
with neurovirulent alphavirus has however not been associated with increased peripheral 
spread in vivo, as could be expected based on the results in IFNAR-1-/- mice (Fragkoudis et 
al., 2007). Thus the exact in vivo effect of this phenotype remains elusive. IFN-γ is involved 
in the neuronal clearance of alphaviruses and it also signals via the JAK/STAT pathway. 
Thus, the observed inhibition of this signaling pathway could relate to reduced clearance of 
virus from neurons (Yin et al., 2009). Supporting this idea, are findings that inhibition of 
JAK/STAT signaling with synthetic JAK inhibitor can abolish the neuroprotective activity of 
IFN-γ against SINV in cultured rat neuronal cells (Burdeinick-Kerr et al., 2009). 
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Figure 5. Sequence of Semliki forest virus pathogenic events in mice. i.v. intravenous; i.p. 
intraperitoneal, s.c. subcutaneous, i.m. intramuscular, BBB: blood-brain barrier. Adapted from 
Atkins (2013), and Ryman & Klimstra (2008). 
 
2.4.3 Host cell responses to alphavirus infection 
SFV RNA or its replication intermediates (i.e. dsRNA) are recognized by the host cell 
cytoplasmic RLRs inducing production of antiviral cytokines. Interestingly, the origin of the 
PAMPs associated with SFV infection has been recently challenged. Results by Nikonov et 
al. (2013) imply that in addition to driving transcription of the viral genome, the viral 
replicase can also use host RNAs as template. These non-viral replication products were 
also shown to be agonists for RIG-I, inducing type I IFN production (Nikonov et al., 2013). 
Of note, the well-defined type I IFN-induced PKR/eIF2a and OAS/RNaseL pathways do not 
seem crucial in inhibiting SINV or SFV replication in vivo (Barry et al., 2009; Ryman and 
Klimstra, 2008; Ryman et al., 2002). ISGs shown to have anti-alphaviral effector function 
include Viperin, zinc-finger antiviral protein (ZAP), IRF-1 and Ifit1 (Hyde et al., 2014; Karki 
et al., 2012; Teng et al., 2012; Zhang et al., 2007). In vivo, the cytokine production after SFV 
infection is notably local and it coincides with viral replication in tissue (Tuittila et al., 
2004). Low levels of systemic type I IFN associated with SFV infection most probably relate 
to low direct infectivity in dendritic cells (Ryman and Klimstra, 2008; Schulz et al., 2005). 
DCs however become activated by phagocytosing SFV infected cells, which leads to cross-
priming of CD8+ cells (Schulz et al., 2005).  
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The mode of cell death following alphavirus infection seems to be dependent on the host 
cell type. As shown by Sammin et al. (1999), upon intranasal administration of SFV in rats, 
immature precursor cells in the olfactory bulb underwent apoptosis while necrotic cell 
death was evident in mature neurons. Necrosis has also been witnessed in cultured rat 
neurons infected with SFV (Glasgow et al., 1997). Nevertheless, the main mechanism 
associated with alphavirus induced cytopathic effect in vitro is apoptosis. In contrast to UV-
inactivated SINV, which is capable of inducing apoptosis despite being unable to replicate 
(Jan and Griffin, 1999), UV-inactivated SFV does not kill cells, indicating that SFV-induced 
apoptosis is replication dependent (Urban et al., 2008). Indeed, although SFV structural 
proteins induce ER stress (Barry et al., 2010) accelerating apoptosis, their expression is not 
needed for the cytopathic effect (Glasgow et al., 1998). In addition to being proapoptotic, 
SFV structural proteins have been shown to inhibit degradation of autophagosomes, which 
leads to autophagosome accumulation (Eng et al., 2012). Interestingly, autophagy has been 
shown to be protective against SINV infection in neurons (Orvedahl et al., 2010). 
SFV-induced apoptosis has been reported to be dependent on Bak-mediated release of 
mitochondrial cytochrome c (Urban et al., 2008), however in a p53-independent fashion  
(Glasgow et al., 1998).  As p53 is commonly mutated in cancer, induction of p53-
independent apoptosis is crucial in inducing cell death in cancer cells. Of note, El Maadidi 
et al. (2014) recently showed that virulent SFV (L10) can induce apoptosis through a newly 
identified MAVS/caspase-8 complex. This event is independent of: Bax/Bak mediated 
permeability of the mitochondrial membrane; Fas-associated death domain protein FADD, 
which is important for death receptor mediated activation of caspase-8; type I IFN signaling 
elements downstream of MAVS; and antiviral effectors activated by IFNAR signaling (El 
Maadidi et al., 2014). These results suggest a link between type I IFN expression and 
apoptosis, both of which can be activated by RIG-I/MDA5 and signal via MAVS.  
Alphaviruses can effectively inhibit both host cell transcription and translation through 
separate mechanisms (Gorchakov et al., 2005). These events are important both for the 
onset of cytopathic effect and viral evasion of antiviral signaling. For the inhibition of 
transcription, Old World alphaviruses utilize nsP2 (Akhrymuk et al., 2012; Garmashova et 
al., 2007). This is in contrast to New World alphaviruses, in which transcriptional shutoff is 
mediated by the capsid protein (Garmashova et al., 2007). During SFV replication, nsP2, 
driven by a nuclear localization signal, translocates into the nucleus where it induces 
ubiquitination and subsequent proteasomal degradation of RNA polymerase II catalytic 
subunit Rbp1 (Akhrymuk et al., 2012).  Results by Breakwell et al. (2007) indicated that SFV 
with a mutated nsP2 nuclear localization signal induced notably higher type I IFN 
production in infected cells compared to wild-type SFV by a mechanism unrelated to 
general cellular shutoff. This suggested that, in addition to the nucleolar function, nsP2 
could have a cytoplasmic function in the inhibition of host protein synthesis. SFV induced 
translation inhibition is largely mediated by phosphorylation of eIF2α (McInerney et al., 
2005). Notably, alphaviruses contain a RNA hairpin loop structure downstream of the 
initiation codon (DLP). This allows the 40S ribosome to initiate translation despite inactive 
eIF2, and facilitates continued viral replication despite PKR activity (Domingo-Gil et al., 
2011).  
In association with increased neurovirulence, some alphavirus strains have been shown 
to inhibit type I IFN-mediated signaling by interfering with the JAK/STAT pathway. 
Studies conducted with VEEV virus and VEEV replicon demonstarted inhibition of STAT1 
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phosphorylation in response to both IFN-β and IFN-γ (type II IFN) by an unknown 
mechanism that was independent of host cell protein synthesis inhibition (Simmons 2009). 
Interestingly, following IFN-γ treatment, VEEV replicon inhibited not only STAT1, but also 
IFN-γ receptor-bound kinases JAK1 and JAK2, while IRNAR1/2-associated JAK1 and TYK2 
and activation of STAT2 under IFN-β stimulus remained unaffected. This indicated that 
VEEV inhibits type I and type II IFN signaling by different mechanisms, and also that 
inhibition of STAT1 activation in response to IFN-β can occur directly, without affecting the 
kinases responsible for phosphorylation. In turn, neurovirulent SINV has been shown to 
inhibit phosphorylation of STAT1 and STAT2 in response to both IFN-β and INF-γ by 
inhibiting the activation TYK2, JAK1 and JAK2 (Simmons et al., 2009). In the case of SFV, 
the neurovirulent strain L10 has been shown to potently replicate in IFN-α pretreated cells, 
while the attenuated V42 strain was severely restricted (Deuber and Pavlovic, 2007).  A 
similar potency to overcome a pre-established antiviral state in host cells has also been 
linked to the neurovirulence of VEEV (Yin et al., 2009). 
It is obvious that many of host cell repsonses to alphavirus infection remain poorly 
understood. One such phenomenon is superinfection exclusion, or homologous interference 
(Strauss and Strauss, 1994). This causes cells infected by alphavirus to become resistant to 
infection by another alphavirus. Studies conducted with SFV indicated that this inhibitory 
effect prevents coinfection in a majority of cells even when viruses were applied following a 
15 min interval (Singh et al., 1997), and that this inhibition took place at the level of viral 
replication (Johnston et al., 1974).  
 
2.4.4 Non-structural protein 3 as an alphavirus neurovirulence factor 
In contrast to other alphaviral nsPs whose roles and functions during viral replication 
have been well characterized, the role of nsP3 is poorly understood. nsP3 is a major 
determinant of SFV neurovirulence (Tuittila et al., 2000, 2004). As shown by Tuittila et al. 
(2000), replacing avirulent rA7(74) nsp3 gene with the corresponding SFV4 gene results in a 
fully neurovirulent phenotype. As was discussed in chapter 2.5.2, glioma targeting can be 
achieved via deletion or mutation of neurovirulence mediating viral genes (for example 
HSV with deleted γ34.5 gene,). In a similar fashion, mutations in the SFV neurovirulence 
genes could attenuate unwanted replication. In this respect nsP3 offers an obvious 
candidate for research. The molecular functions and host protein interactions of nsP3 are 
discussed below. 
NsP3 consists of three domains: a N-terminal macrodomain, which is evolutionarily 
conserved in all kingdoms of life; an alphavirus unique domain, which is conserved only 
within alphaviral nsP3 proteins; and a C-terminal hypervariable domain with low sequence 
similarity between alphaviruses. The non-conserved C-terminal tails of SFV and SINV nsP3 
are phosphorylated (Lastarza et al., 1994; Vihinen et al., 2001). Notably, deletion of the C-
terminal, phosphorylated region severely attenuated neurovirulence (Vihinen et al., 2001). 
As part of the alphavirus replication complex, nsP3 has been shown to be required for 
minus-strand and sub-genomic RNA synthesis (LaStarza et al., 1994), and it possibly has a 
function in promoter recognition as well (Michel et al., 2007). Additionally, the signal for 
RC internalization into cytoplasmic vesicles is mediated by nsP3 as part of nsP123 (Salonen 
et al., 2003). 
Many alphaviruses contain opal termination codon near the C-terminal end of nsP3 
(Figure 4), leading to the expression of two nsP3 isoforms. The longer nsP3 isoforms of SFV 
24 
 
 
and SINV, which is produced by translational read-through of the stop codon, were 
reported to be conditionally unstable due to a C-terminal destabilizing fragment 
(DVLRLGRAGA in SFV4), which induces proteosomal degradation (Varjak et al., 2010). In 
the later stages of the replication (>3h pi.), nsP3 becomes more stable either with the help of 
other viral replicase components or due to replication mediated inhibition of degradation 
(Varjak et al., 2010). Of note, deletion of the degradation signal from SFV4 decreased the 
number of successfully infected cells indicating that temporally controlled nsP3 
degradation is important in the establishment of SFV4 replication (Varjak et al., 2010). 
However, the exact reason for this is not known. 
Alphaviral nsP3 has been shown to mediate many host protein interactions, which are 
implicated in the establishment of the viral replication complex, and in the modulation of 
host cell responses in favor of replication. Indeed, nsP3 can localize not only in the 
replication complex but also in cytoplasmic aggregates in infected cells (Salonen et al., 
2003). Multiple host proteins have been detected to interact with SIN nsP3 in rat fibroblasts 
cells (Cristea et al., 2006). Such host factors included Ras-GAP SH3 domain–binding protein 
(G3BP), 14-3-3 proteins, ribosomal proteins, heat shock proteins and RNA helicases. Some 
interactions were also observed to be temporally controlled. One of the best characterized 
host cell interactions is nsP3 binding to G3BP, an event which inhibits the formation of 
stress granules during SFV, CHKV and SINV infection (Fros et al., 2012; Panas et al., 2012, 
2014). Stress granules are induced by many types of environmental stress, acting as 
translational silent storage for mRNA. They are also induced by viruses and possibly have 
function in the antiviral defense of the cell (Lloyd, 2012). Thus it can be suggested that 
binding of G3BP is part of the alphaviral repertoire of countermeasures against antiviral 
signaling. 
The nsP3 C-terminal domains (HVD) of SINV (Old World Alphavirus) and VEEV (New 
World Alphavirus) mediate distinctly different host protein interactions (Foy et al., 2013). 
However, the HVD domains of these viruses are interchangeable: swapping the domains 
did not affect viral replication although it altered nsP3 cellular distribution and formation 
of protein complexes with host factors (Foy et al., 2013). Thus it is propable that nsP3s of 
Old and New World alphaviruses ultimately affect the same cellular processes, but via 
different host protein interactions.  
2.4.5 Alphaviruses as oncolytic agents 
The replicative SFV vector VA7 is derived from the attenuated A7(74) strain, and has 
shown oncolytic potency in many tumor xenograft models. These include human 
melanoma A2058, osteosarcoma K7M3 and lung cancer A549 (Heikkilä et al., 2010; Ketola et 
al., 2008; Määttä et al., 2008; Vähä-Koskela et al., 2006). Because of the natural tropism 
toward CNS tissues, SFV is a promising candidate for the treatment of primary and 
secondary brain tumors. Indeed, as shown by Heikkilä et al. (2010), a single systemic dose 
of VA7 resulted in complete eradication of orthotopic human U87 gliomas in 
immunodeficient mice. In a syngeneic rat BT4C glioma model intratumoral injection of SFV 
A7(74) showed initial delay in tumor growth (Määttä et al., 2007) demanding further 
evaluation of the antitumor effect in immunocompetent glioma models.  
The exact reasons for the attenuated phenotype of A7(74) and the derivative vector VA7-
EGFP are unknown, but could be associated with reduced capability to overcome antiviral 
effects of type I IFN (Deuber and Pavlovic, 2007; Simmons et al., 2009, 2010). As was 
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discussed in chapter 2.4.4, the main determinant of SFV neurovirulence seems to reside in 
the nsP3 (Tuittila and Hinkkanen, 2003; Tuittila et al., 2000). However, the molecular 
functions of nsP3, including possible inhibition of antiviral signaling, are not well 
understood.  
Due to the suggested link between neuronal replication capability and the potency to 
resist antiviral action of type I IFN, the possibility to utilize neurovirulent alphavirus clones 
against otherwise resistant tumors is an intriguing concept. However, studies on more 
virulent SFV strains in mouse models are limited because of the severe neuropathogenicity. 
In addition, combinations of immunosupressive agents including CPA (Bradish et al., 
1975a), cyclosporine (Fazakerley and Webb, 1987b), linomide (Peltoniemi et al., 2002), 
tunicamycin (Singh et al., 1987), aurathiolates (Scallan and Fazakerley, 1999) and myocrisin  
(Bradish et al., 1975b; Oaten et al., 1980) have all been shown to increase neuronal 
replication of avirulent strains. Taken together, although SFV is not considered to be a 
severe human pathogen, strategies to decrease chances of unwanted neuronal replication 
would be demanded in order to harness the full potency of alphaviruses and to ensure 
safety in clinical settings. Neurovirulent SFV4 has been used to treat subcutaneous CT-26 
(mouse colon adenocarcinoma) and K-BALB (murine sarcoma virus-transformed 
fibroblasts) in mice immunized with SFV replicon (Smyth et al., 2005). In this study, SFV4 
was shown to replicate in tumors cells, which correlated with reduced tumor size. 
However, long-term responses were not obtained. Importantly, intratumoral injection of 
SFV4 in immunized mice resulted in notable swelling of the tumors, an effect that was not 
observed in naïve mice, indicating a strong immune reaction against the virus.  
Not only SFV, but also other alphaviruses CHIKV and SINV have shown oncolytic 
effects in mice. CHIKV infection in human U87 glioma cells was found to induce autophagy 
and the production of proinflammatory cytokines (Abraham et al., 2013). Also, SINV 
infection in IFNAR-/- syngeneic tumors was shown to induce infiltration of CD8+ and CD4+ 
T cells (Huang et al., 2012). Importantly, depletion of CD8+ cells also significantly decreased 
antitumor potency of SINV therapy, indicating an immunostimulatory potential of 
alphavirus mediated oncolytic virotherapy. Indeed, alphavirus replicons expressing TAAs 
or immunostimulatory cytokines have proven potency in cancer immunotherapy 
applications (Granot et al., 2014; Rodriguez-Madoz et al., 2014). Notably, only relatively 
short term expression of IL-12, when combined with SFV replicon-induced cytopathic effect 
and expression of type I IFNs, was sufficient to induce an antitumor effect (Melero et al., 
2015; Rodriguez-Madoz et al., 2014). In a similar fashion, short term SINV replicon-derived 
expression of LacZ was sufficient to induce a CD8+ -dependent therapeutic effect against 
LacZ-expressing CT26 tumors (Granot et al., 2014). Alphavirus replicon-based 
immunotherapies have also raised interest in clinical settings. Patients are currently being 
recruited to phase I trials (clinicaltrials.gov identifier: NCT01526473 and NCT01890213) 
using VEEV replicons expressing breast cancer associated HER-2 or colon cancer associated 
CEA antigens (AVX901 and AVX701). 
Taken together, alphaviruses exhibit favorable features for oncolytic virotherapy. High 
serum viremia and capability to penetrate the BBB provide a good starting point in the 
design of systemically administered antiglioma therapy.  
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2.5 microRNA TECHNOLOGY 
MicroRNAs (miRNAs) are small, 19-24 nucleotide long non-coding RNAs transcribed by 
both plant and animal cells. They are part of the RNA interference machinery and are 
important posttranscriptional regulators of gene expression. Although the evolutionary 
origin of RNA interference was to provide defense against harmful nucleic acids such as 
DNA and RNA that are produced during viral replication, viruses have evolved to utilize 
this machinery for their own purposes. Indeed, viruses are not only susceptible to the 
regulatory function of host miRNAs but also express their own miRNAs to modulate 
cellular responses and/or translation of their own genes (Guo and Steitz, 2014).  
Consequently, viruses can also be engineered to carry artificial miRNA target sites that 
inhibit their replication in specific miRNA-expressing cells.  
2.5.1. microRNA biogenesis and function 
In animal cells, miRNAs are first transcribed by RNA polymerase II as long pri-miRNAs 
containing an imperfectly paired stem (~33bp) with a terminal loop and flanking regions. 
These pri-miRNAs are capped and polyadenylated. The stem loop is first cleaved inside the 
nucleus by the Drosha-DGCR8 complex, producing pre-miRNA that is then exported to the 
cytoplasm (Kim, 2005). Alternatively, miRNAs can be generated from short spliced introns 
with pre-miRNA hairpin mimicking structures called mirtrons (Ruby et al., 2007). 
In the cytoplasm, the pre-miRNA terminal loop is excised by Dicer enzyme, generating a 
mature miRNA duplex (Kim, 2005). The miRNA duplex is unwound upon association with 
functionally important Argonaut (Ago) protein forming an Ago/miRNA complex. This 
complex then associates with other proteins such as GW182, forming the miRISC complex  
(Huntzinger and Izaurralde, 2011). The mechanism of miRNA strand selection from 
miRNA duplex is not strict, as either strand can be incorporated into the final miRISC 
complex. The most commonly incorporated strand is termed the miRNA strand. In the 
miRISC complex, the miRNA acts as an adaptor that binds to complementary sequences 
(miRNA target sites) in messenger RNAs. Binding of targets with imperfect base pairing 
with miRNA promotes translational repression, while in the case of perfect 
complementarity, the targeted mRNA is degrated (Huntzinger and Izaurralde, 2011). 
Recent results indicated that in addition to targeting cytoplasmic mRNAs, mature miRISC 
complexes can also translocate to the nucleus (Roberts, 2014). The function of nuclear 
miRNAs is still not properly understood, but there is evidence of gene regulatory functions 
at both postranscriptional and transcriptional levels (Roberts, 2014). A schematic picture of 
miRNA biogenesis and function is presented in Figure 6. 
The expression profile of different miRNAs is specific to tissue type and developmental 
stage (Landgraf et al., 2007). Abnormal miRNA expression is associated with many 
different types of diseases including cancer (Huntzinger and Izaurralde, 2011). As miRNAs 
can be transferred form one cell to another in microvesicles or exosomes and they can also 
be found in human serum (so called circulating miRNAs), they are considered promising 
cancer biomarkers (Kosaka et al., 2010). Importantly, as perfect complementarity between 
miRNA and its target mRNA is not strictly required, a single miRNA can target hundreds 
of different mRNAs. Also, inhibition of a specific miRNA may have only a modest effect on 
overall gene expression, indicating that the same transcript can be targeted by multiple 
different miRNAs. Indeed, as much as one third of human genes are thought to be under 
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miRNA regulation (Lewis et al., 2005). To date, 1881 miRNA sequences have been 
identified in humans and 1193 in mice (miRBase:  http://www.mirbase.org, University of 
Manchester, accessed February 2015).  
 
 
Figure 6. Biogenesis and function of miRNAs. Pre-miRNAs can arise from pol II-driven 
expression of Drosha-cleaved pri-miRNAs or mirtrons. In the cytoplasm, pre-miRNAs are 
processed further by Dicer to form mature miRNAs that associate with Ago to form RISC 
complex. RISC complex targets messenger RNAs with complementary sequences to miRNA and 
induce their translational arrest and/or degradation. (M. Martikainen) 
2.5.2 Targeting oncolytic virus replication to glioma with microRNA target sites 
The cell/tissue specificity of host miRNA expression patterns can be utilized to generate 
viruses that are specifically inhibited in non-target tissues. In this approach, referred to as 
miRNA-mediated tissue detargeting, complementary sequences against specific miRNAs 
are inserted into the viral genome. This strategy can be successfully used to alter the 
replication of both RNA and DNA viruses in a cell type-specific manner. As miRNAs target 
mRNAs, inhibition of DNA virus replication takes place at the level of viral gene 
transcription. Thereby the system can be used to inhibit translation of specific viral 
proteins. When incorporated into RNA virus, miRNA target sites can be used to directly 
target the viral genome.  
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A clear advantage of miRNA-mediated detargeting is that miRNA target sites operate at 
the level of RNA, allowing inhibition of virus replication without deletions or mutations at 
the protein level. Consequently, replication of oncolytic virus can be attenuated in healthy 
cells by inserting complementary sequence elements to miRNAs that are expressed in these 
cells. Thus there is no need to abrogate essential mechanisms that promote replication in 
cancer cells. Targeting viral replication by exploiting miRNA-mediated degradation 
provides a way for rational design of oncolytic viruses, provided that the miRNA 
expression profile of the targeted cells/tissue is known.  
Multiple miRNAs expressed in normal brain tissue are downregulated in GBM, thus 
providing several candidate miRNAs to be used in targeting of viruses. Examples of such 
miRNAs are miR-7, miR-124, miR-125, miR-128, miR-146b, miR-218 and let-7a (Karsy et al., 
2012). MiR-124, miR-7 and let-7a are also among the most highly expressed miRNAs in 
normal human brain tissue thus serving as good candidate miRNAs for detargeting of 
healthy brain cells (Shao et al., 2010). Indeed, target sites against miRNAs that are 
downregulated in GBM have been successfully used to control CNS replication of oncolytic 
HSV and measles virus in preclinical mouse glioma models (Mazzacurati 2015; Leber 2011). 
Targeting of HSV, a dsDNA virus, was achieved by insertion of four copies of miR-124 
target sequences in the 3’UTR of the ICP4 gene. In the case of the measles virus, which is a 
negative-sense ssRNA virus, three copies of miR-7 targets were inserted in the 3’UTR of the 
viral fusion gene, which blocked late stage replication in miR-7 expressing cells (Leber et 
al., 2011). In both cases oncolytic replication in human glioma xenograft was retained, while 
neuronal replication was attenuated. 
Although the design of miRNA-targeted virus can be simple, there are some important 
aspects to be considered. One factor which is hard to control is the secondary structure of 
the targeted RNA transcript. It is known that the ability of host miRNAs to bind their 
targets is greatly affected by RNA secondary structure. (Gismondi et al., 2014; Zhang et al., 
2013). This means that the presence of miRNA target site alone is not enough for targeting 
effect, but that the target site has to also be accessible to the RISC complex. Viruses are also 
known to escape targeting due to mutations or deletions in the target sites. As RNA viruses 
encode their own RNA polymerases that lack proofreading activity, they can quickly yield 
populations of mutated clones. Therefore, insertion of multiple target sites into different 
loci in the viral genome and, if possible, within open reading frames increases success of 
miRNA-targeting (Kueberuwa et al., 2014; Teterina et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
 
3. Aims of the study 
The aims of this thesis were to study the anti-tumoral potency of oncolytic SFV in 
immunocompetent mouse glioma models, to develop means to engineer SFV for selective 
and enhanced replication in tumors, and to elaborate and apply strategies to inhibit virus 
replication in neurons. 
 
The specific aims for the four parts (I-IV) of this thesis were as follows: 
I  To assess the oncolytic potency of the attenuated SFV vector VA7 in syngeneic 
mouse glioma models   
II  To determine the role of nsP3 proline-rich regions in the regulation of SFV 
neurovirulence and to study the possible applications for tumor targeting 
III  To engineer a microRNA-targeted SFV for oncolytic therapy  
IV  To evaluate the infection patterns and the oncolytic potency of neuron-
detargeted SFV4 against resistant CT-2A mouse glioma 
An additional aim was to elucidate the possible role of viral RNA secondary structure in 
SFV neuropathogenesis. The results of this related unpublished work are also presented in 
this thesis. 
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4 Materials and methods 
4.1 CELL LINES AND VIRUSES 
Description of the different cell lines and culture media used in the studies is presented in 
Table 2.  
Table 2. Cell lines that were used in the studies. *(Vähä-Koskela et al., 2007). DMEM: 
Dulbeccos’s Modified Eagle Medium, FCS: Fetal Bovine Serum, L-glut: L-glutamine, Pen-Strep: 
Penicillin-streptomycin, MEM: Minimum Essential Medium Eagle, HEPES: (4-[2-hydroxyethyl]-1-
piperazineethanesulfonic acid). 
Cells Description Source Culture medium Study 
BHK-21 Syrian hamster kidney fibroblasts ATCC 
DMEM, 10% FBS, 1% L-
glut, 1% Pen-strep I-IV 
CT-2A Mouse glioma Thomas Seyfried, Boston College 
RPMI-1640, 10% FBS, 
1% L-glut, 1% Pen-strep I, IV 
CT-2A-
Fluc 
Firefly luciferase 
expressing CT-2A 
mouse glioma 
Jan Brun, 
Children's Hospital 
of Eastern Ontario 
RPMI-1640, 10% FBS, 
1% L-glut, 1% Pen-strep I, IV 
DBT Mouse glioma 
Daniel Silbergeld, 
University of 
Washington 
DMEM, 10% FBS, 1% L-
glut, 1% Pen-strep I 
GBM 
003, 027 
and 038 
Human 
glioblastoma 
Cell lines established 
from patient 
samples (Kuopio 
University Hospital) 
DMEM/F12, 10% FBS, 
1% glutamax, 1% Pen-
strep, 1.25μg/ml 
fungizone 
IV 
GL261 Mouse glioma G. Safrany DMEM, 10% FBS, 1% L-glut, 1% Pen-strep I 
HeLa Human cervical cancer ATCC 
DMEM, 10% FBS, 1% L-
glut, 1% Pen-strep II, III 
Huh7 
Human 
hepatocellular 
carcinoma 
Mark Harris DMEM, 10% FBS, 1% L-glut, 1% Pen-strep III 
MBA-13 
CNPase-positive 
mouse brain cell 
line* 
Aimo Salmi, 
University of Turku 
MEM, 5% FBS, 1% Pen-
strep I 
N2A mouse neuroblastoma ATCC 
DMEM, 10% FBS, 1% L-
glut, 1% Pen-strep II 
Tera-2 
Human 
embryonal 
carcinoma 
ATCC DMEM, 10% FBS, 1% L-glut, 1% Pen-strep III 
U87 Human glioma ATCC DMEM, 10% FBS, 1% L-glut, 1% Pen-strep I, III 
U87-Fluc Human glioma Established in the group 
MEM, 10% FBS, 1% L-
glut, 1% Pen-strep I 
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Table 2 continued. 
Establishement of human glioblastoma cell lines (IV) 
Research with human glioblastoma samples was conducted according to ethical 
guidelines approved by the Research Ethics Committee of the Hospital District of Northern 
Savo. Glioblastoma samples were from 3 patients (2 males and 1 female, aged 67-68 years) 
operated in the Kuopio University Hospital during July 2012 - February 2014. Immediately 
after removal the samples were transported to the cell culturing laboratory in cold Opti-
MEM Reduced serum medium (Gibco), and tissue parts containing blood were removed. 
The remaining glioma piece was cut with scalpel and McIlwain Tissue chopper (thickness 
500 μm) followed by passing through a 21-gauge needle. After subsequent trituration by 
pipetting, the cells were centrifuged (1000 g, for 4 min) and red blood cells were lysed by 
ammonium chloride (Stem Cell Technologies) followed by two washes with PBS. Finally 
the cells were suspended into small volume of culture medium (Table 2) and seeded into 
cell culture flasks. 
GL261 glioma explants (I) 
Tumor tissue was collected from intracranial GL261 glioma-bearing C57BL/6 mice. 
Glioma tissue was passed through a fine metal mesh directly into cell culture plates and 
cells were cultured at same conditions as GL261 cell line (Table 2). 
Production of SFV (I-IV) 
SFV4-miRT122 and SFV4-miRT124 were created using the original pSP6-SFV4 plasmid 
which contains the genomic sequence of SFV4 as follows; novel NdeI site was first created 
by PCR upstream of the protease cleavage site sequence between nsP3 and nsP4, followed 
by insertion of a synthetic DNA sequence containing the protease cleavage site and miRNA 
targeting elements. This synthetic DNA sequence was inserted between the engineered 
NdeI and naturally existing XhoI sites.  
The FM14-silent clone was generated by in vitro mutagenesis (Change-IT kit, 
Affymetrix). First an intermediate cloning plasmid was created by inserting the SacI-NotI 
fragment from FM14 into pBlu2KSP. Finally the mutated SacI-NotI fragment was subcloned 
back to the FM14 plasmid. The presence of mutations in the resulting plasmid was 
confirmed by sequencing. 
Silent mutations were generated with the following 5’-phosphorylated primers (mutated 
nucleic acids underlined): 
Forward: 5’- GAGTTAAGAGAGCAGACAT C GCCACGTGTACAGAAGC-3’ 
Reverse: 5’- GGTTGAATTTCG TACCTT C GAAGTACGAGTACAGCGACC-3’ 
Cells Description Source Culture medium Study 
Vero(B) African green monkey kidney 
University of 
Turku 
DMEM, 5% FBS, 1% L-glut, 
1% Pen-strep, 10mM HEPES  I-IV 
293FT 
Human embryonic 
kidney, expressing 
SV40 large T 
antigen 
Life Technologies 
DMEM (high glucose), 10% 
FBS, 0.1mM Non-Essential 
Amino Acids, 6mM L-glut, 
1mM sodium pyruvate, 1% 
Pen-strep, 500μg/ml Geniticin 
II 
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Deletion of the proline-rich sequence form SFV was performed by PCR in an 
intermediate pEBB plasmid construct containing the SacI-NotI fragment from pSP6-SFV4. 
The new ΔP1+2 containing SacI-NotI fragment excised from the resulting 
pEBB/SFV4SacNotΔP1+2 was then subcloned back to the original pSP6-SFV4 plasmid. 
Primary virus preparations were produced from in vitro transcribed virus RNA 
(mMESSAGE mMACHINE SP6-kit, Ambion) which were transfected (TransIT-mRNA kit, 
Mirus Bio) into BHK-21 cells seeded on 6-well plates. The supernantant from transfected 
cells was collected 48 hours post transfection and used to infect larger cultures of BHK-21 
cells. Virus containing culture medium was collected 24h pi., centrifuged to remove cell 
debris and filtered through 0,2 μm syringe filters. The filtrate was divided into aliquotes 
and stored at -70oC. 
Virus stocks of clones rA7(74), rA7(74)-V4Del-arg, CMW12, CMW3, CMW34 and FM14 
were originally produced by Minna Tuittila (Tuittila and Hinkkanen, 2003; Tuittila et al., 
2000), and used in experiments after confirmation of the virus titer. L10 virus was 
propagated further in BHK-21 cells by directly infecting the cells with the original stock. 
Determination of the infectious titer was done in Vero(B) cells by plaque titration assay. 
Briefly, Vero(B) cells seeded on 12-well plates were infected with serial dilutions of virus 
preparations and incubated for 1h after which the medium was replaced with 0.4% low 
melting-point agarose. The plates were incubated for 48h in an incubator (+37°C in 5% CO2) 
after which the formed plaques were visualized by crystal violet staining. List of different 
SFV strains and clones used is presented in Table 3. 
 
Table 3. SFV strains and clones that were used in the studies. * described by Tuittila et al., 
(2000). ** Described by Tuittila & Hinkkanen (2003).  
Virus Description Study 
rA7(74) Neuroattenuated SFV strain Figure 9 
SFV4 Neurovirulent SFV strain II, III, IV,  Figure 8, 9 and 10 
L10 Neurovirulent SFV prototype strain            (from J. Fazakerley) IV 
VA7-EGFP EGFP expressing vector derived from attenuated rA7(74) I, IV and Figure 7 
SFV4-miRT122 SFV4 with 6 copies of miR-122 targets III 
SFV4-miRT124 SFV4 with 6 copies of miR-124 targets III 
SFV4-ΔP1+P2 SFV4 with deleted proline-rich regions II and Figure 8 
CMW12* rA7(74) with nsP1-2 region from SFV4 IV 
CMW3* rA7(74) with nsP3 region from SFV4 IV 
CMW34* rA7(74) with nsP3-4 region from SFV4 IV 
rA7(74)-V4Del-arg* rA7(74) with inserted V4 and opal to R mutation Figure 9 
FM14** rA7(74)-V4Del-arg with V11I and L201F mutations Figure 9 and 10 
FM14-silent FM14 with silent mutations at I11 and F201 Figure 9 and 10 
 
34 
 
 
4.2 IN VITRO STUDIES 
Western blotting (I, III and IV) 
P-STAT1 (Tyr701), STAT1, P-IRF3 (Ser396), and β-actin loading control were detected as 
follows (IV). 2 x 105 Vero(B) or 4 x 105 CT-2A-Fluc cells were seeded on 12-well plates and 
infected with SFV (rA774, VA7-EGFP, L10, SFV4 or SFV4-miRT124) using a MOI of 10. In 
order to induce phosphorylation of STAT1, the culture medium was replaced with medium 
containing 1000 units/ml recombinant IFN-β at time points 4 to 10 hours post infection. 
Human (Nordik Biosite) and mouse (Sigma-Aldrich) IFN-β were used for treatment of 
Vero(B) and CT-2A-Fluc cells respectively. Cells were incubated in IFN-containing medium 
at +37°C for 20 min, followed by washing with cold PBS and lysis in radio-
immunoprecipitation assay buffer (RIPA, containing 50 mM Tris-HCl [pH 8.0], 150 mM 
NaCl, 1 mM EDTA, 1% nonidet P-40, 0.5% deoxycholate, 0.1% SDS with Complete Mini 
protease inhibitor cocktail [Roche] and phosphatase inhibitor cocktail [Roche]). Cell lysates 
were collected by scraping and stored at -20°C until analyzed.  
Protein concentration of the samples was determined by Bradford Bio-Rad Protein Assay 
Dye Reagent (Bio-Rad), using the microtiter plate protocol provided by the manufacturer. 
Standards were prepared from bovine serum albumin. Once the protein concentration was 
determined the samples were boiled 5min at 95°C with 1x loading buffer (10x stock: 0.45M 
Tris-HCl, pH 6.5, 0.5M DDT, 10% SDS, Bromophenol Blue, <50% glycerol) and stored at 
+4°C. Protein samples (25 μg/well) were separated on 10% SDS-PAGE gel and transferred 
to Hybond-ECL membranes (GE Healthcare). Transfer and blocking with 5 % BSA/TBS was 
performed according to Amersham ECL Plex Western blotting system instructions (GE 
Healthcare). 
Detection of wanted proteins was done with specific primary antibodies against STAT1 
(rabbit polyclonal, BD transduction laboratories, cat. 61011), Tyr701 phosphorylated STAT1 
(rabbit monoclonal, D4A7, Cell Signaling Technology,), Ser396 phosphorylated IRF-3 
(rabbit monoclonal, 4D4G, Cell Signaling Technology) and β-actin (mouse monoclonal, C4, 
Santa Cruz Biotechnology) together with anti-rabbit-Cy5 and anti-mouse-Cy3 secondary 
antibodies (according to the Amersham ECL Plex Western blotting system). Typhoon 
scanner (GE Healthcare) was used for fluorescence imaging of the membranes. 
Quantification of protein band intensities was done using ImageJ software.  
In part I and III detection of SFV proteins was done using rabbit anti-SFV prepared in 
house) which recognizes envelope and capsid proteins (I, III), or rabbit anti-nsP3 and anti-
nsP4 (Tero Ahola, University of Helsinki) as primary antibodies. In part I, OAS was 
detected with rabbit anti-OAS (Ilkka Julkunen, THL, Finland) primary antibody.  
Quantifying type I IFN sensitivity with cell viability assay (IV) 
Cell viability measurements were done in a 96-well format by plating 10 000 human 
glioblastoma cells derived from patient samples, or 40 000 CT-2A-Fluc cells per well. On the 
following day the cells were administered fresh medium with 0 to 1000 Units/ml of 
recombinant IFN-β. Human IFN-β (Nordic Biosite) was used for human cells and mouse 
IFN-β (Sigma-Aldrich) for mouse cells. After adding the IFN-containing medium the cells 
were infected with virus at a MOI of 10. Cell viability was measured 48 hours after infection 
using Cell Proliferation Kit I (Roche) according to the manufacturer’s instructions. 
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IFN-β quantitation by ELISA (I and IV) 
Measurement of mouse IFN-β was done from medium samples collected form infected 
cells using Verikine IFNβ ELISA kit (PBL InterferonSource) according to manufacturer’s 
instructions. 
Plaque expansion assay (IV) 
CT-2A-Fluc cells (250 000/well) were seeded on 6-well plates and covered with 1% 
agarose and 2% penicillin/streptomycin containing culture medium. Approximately a 3mm 
diameter piece was removed from the solidified agarose cover using a pipette tip. VA7-
EGFP (5000 PFU in 10μl volume of culture medium) was added to the punctured agarose 
with or without 10μM JAK inhibitor I (Santa Cruz Biotechnology). The virus spread was 
imaged for 4 days with Leica M165 fluorescence stereomicroscope. 
Immunofluorescence (II and IV) 
Infected HeLa and N2A cells cultured on glass coverslips (II) were fixed 20 min  with 4% 
PFA in PBS followed by 10 min quenching with 50 mM NH4Cl, followed by 2 min 
permeabilization with 0.1% Triton X-100. Washing between these steps was done using 
0.2% BSA/PBS. Primary and secondary antibody incubations were done at RT, 1h each with 
washing steps in between. Mounting was done using Mowiol 4-88 (Calbiochem) with 2.5% 
DABCO (1,4-diazabicyclo(2,2,2) octane; Sigma). 
Primary antibodies used in part II were rabbit or guinea pig anti-nsP3 (Tero Ahola, 
University of Helsinki), mouse J2 anti-dsRNA (Scicons). Rabbit H100 anti-amphiphysin-2, 
mouse 2F11 anti-mphiphysin-2, or goat N19 anti-amphiphysin-1 (Santa Cruz 
Biotechnology). Secondary antibodies (anti-mouse, anti-rabbit, anti-guinea pig or anti-goat) 
were conjugated with Alexa-488, Alexa-568, Alexa-647 (New England Biolabs) or Cy5 
(Abcam).  
For the detection of tumor-reactive antibodies in mouse serum (IV), mouse tumor cells 
were cultured on glass coverslips coated with 10μg/ml laminin (Sigma-Aldrich). Stainings 
were done as above using 1:100 diluted (in 3% BSA/PBS) mouse serum samples as the 
primary antibody. Alexa495-conjugated anti-rabbit (LifeTechnologies) was used as a 
secondary antibody. Cell nuclei were stained with 5μM DAPI (Molecular probes) for 15 
min and coverslips were mounted with Fluoroshield (Sigma-Aldrich). Images were 
obtained with fluorescence confocal microscope (Leica TCS SP5 in part II, and Zeiss LSM 
700 in part IV). 
 
Quantitative PCR (II and III) 
RNA from cells was extracted by Trizol (Invitrogen, II) or GenElute mammalian total 
RNAminiprep kit (Sigma-Aldrich, III). cDNA synthesis was done by High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, II) or Fermentas RevertAid Moloney 
murine leukemia virus (M-MuLV) reverse transcriptase (ThermoFisher Scientific, III). 
Quantitative PCR was performed using LightCycler 480 and SYBR Green I Master Mix 
(Roche, II) or Mx3005P quantitative PCR System (Stratagene) with Power SYBR green PCR 
master mix (Applied Biosystems, III). 
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Primers used in part II were as follows: 
SFV nsP1 forward: TCTTTGCAGAAGGCATTTCC 
SFV nsP1 reverse: GCATGGTCATTTGGTGTGAC 
SIN nsP1 forward: GAATGTTTTCCGAGCACCAG 
SIN nsP1 reverse: CCGGGTCTTCTGGACTACG 
BHK GAPDH forward: ATCCCACCAACATCAAATGG 
BHK GAPDH reverse: AAGACGCCAGTAGACTCCACA 
HeLa GAPDH forward: AGCCACATCGCTCAGACAC 
HeLa GAPDH reverse: GCCCAATACGACCAAATCC.  
 
Primers used in part III were as follows: 
SFV +strand forward primer, TGGAGCTGACCACAGACTTG 
SFV +strand reverse primer, GGCCACAACGTCAGTATCTC 
Phage display (II) 
Biotin-tagged nsP3 proteins were expressed in 293FT cells and precipitated with 
streptavidin-coated magnetic beads (Dynabeads M-280-Streptavidin, Invitrogen). The 
precipitate was incubated for 2 h with human SH3 phage library (109 to 1010 colony forming 
units in PBS-Tween supplemented with 2.5% non-fat milk) as described by Kärkkäinen et 
al. (2006). The nsP3-bound phages were incubated with TG1 bacteria at 37°C for 1 h 
followed by seeding of the infected bacteria to LB-ampicillin plates. Sequencing of 
phagemides from individual bacterial colonies was performed to identify the nsP3-
interacting SH3 domains. 
Protein pull-down assay (II)  
293FT cells were transfected with expression vectors encoding different biotin acceptor 
domain-tagged nsP3 proteins together with equimolar amount of a vector expressing Myc 
epitope-tagged amphiphysin 1 or amphiphysin 2 (GenBank accession number BC034376 
and BC004101) by calcium phosphate precipitation method. Cell were collected in PBG 
buffer (PBS with 10% glycerol and 0.5% Tween-20) with complete protease inhibitor 
(Roche) and lysed by sonication. Precipitation of nsP3-amphiphysin complexes was done 
using streptavidin-coated magnetic beads (Dynabeads M-280-Streptavidin, Invitrogen). 
Cell extracts and precipitated samples were analyzed by western blotting using mouse anti-
Myc primary antibody (M-5546, Sigma-Aldrich) in combination with IRDye680-labeled 
anti-mouse secondary antibody (LI-COR Biosciences). NsP3 proteins were detected with 
IRDye 800CW-labelled streptavidin (LI-COR Biosciences). 
The SFV nsP3 interaction with endogenous amphiphysin-2 in infected cells was done by 
precipitating nsP3 with pig anti-nsP3 antibody (Prof. Tero Ahola, University of Helsinki), 
immobilized onto Protein-A-Sepharose resin (Invitrogen), for cell lysates. NsP3-
amphiphysin protein complexes were immunoblotted with rabbit anti-amphiphysin-2 
(Santa Cruz Biotechnology) or rabbit anti-nsP3 (Tero Ahola, University of Helsinki) 
combined with HRP-conjugated anti-rabbit secondary antibodies and chemiluminescent 
HRP substrate (Millipore). 
siRNA experiments (II) 
Amphiphysin2 was silenced from HeLa cells with transfection of 20nM siRNAs with 
Oligofectamine Transfection Reagent (Invitrogen). The siRNAs used were Dharmacon ON-
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TARGETplus smart pool L-008246-00-0005 (sequences: GACAUCAAGUCACGCAUUG; 
GAACAGCCGCG UAGGUUUC; ACAACGACCUGCUGUGGAU; CCAGCAACGUGCA 
GAAGAA) or Qiagen FlexiTube GeneSolution for BIN1 Hs_Bin1_5: 
CCGGCGGAATTCACCAGTGTT; Hs_Bin1_6: CTGGTCGGCCTGGAGAAGCAA; 
Hs_Bin1_2: ATGGCAGAGATGGGCAGTAAA; Hs_Bin1_3: 
CAAGCTCAACCAGAACCTCAA. ONTARGETplus Non-Targeting Pool or Qiagen 
Negative Control siRNA were used as non-specific siRNA controls. Viability of siRNA 
transfected cells was measured by CellTiter-Glo Luminescent Cell Viability Assay 
(Promega). 68 hours after siRNA transfection, the cells were infected using a MOI of 5. Cells 
were lysed 5 hours post infection with Trizol-reagent (Invitrogen) and analyzed with 
quantitative PCR. Alternatively, virus replication in cells infected with Renilla luciferase 
expressing SFV-Rluc (Kujala et al., 2001) was analyzed by Renilla Luciferase Assay System 
(Promega). 
Statistical analysis (I-IV) 
Statistical analysis was done with GraphPad Prism (GraphPad Software) using unpaired, 
two-tailed Student’s t-test (I, III and IV) or by using Microsoft Excel Students t-test (II).  
4.3 IN VIVO STUDIES 
Mouse strains utilized in the studies are listed in Table 4. 
Table 4. Mouse strains that were used in the studies. All mice used in the studies were over 4 
weeks old females. 
Strain Breeder Phenotype Study 
B6.Cg/NTac-Foxn1nu NE10 Taconic athymic (defective T-cell immunity) I 
C57BL/6JOlaHsd Bred in Kuopio 
immunocompetent  
C57BL/6 mice 
I, IV, 
Figure 7 
BALB/cAnNTac Taconic immunocompetent  BALB/c mice 
II, III, 
Figure 8, 9 and 10 
 
The animal experiments with replicative SFV were performed at biosafety 2 containment 
level following the guidelines of the national committee of animal welfare. 
For implantation of cancer cells, cultured GL261 or CT-2A-Fluc cells were trypsinized, 
centrifuged (+4oC, 1000 g, 4 min) and re-suspended in Opti-MEM (Life Technologies). The 
concentration of viable cells was calculated from the Trypan Blue stained sample in Bürker 
chamber. The volume of cell suspension was adjusted with Opti-MEM to achieve required 
cell concentration (10 000 cells/5μl or 50 000 cells/5μl). 
The mice were anesthesized with intraperitoneal administration of medetomidine 
(1mg/kg) and ketamine (75 mg/kg) and kept under anesthesia with isoflurane gas during 
the operation.  Analgesia was supplemented with 5 mg/kg subcutaneous carprofen. The 
scalp was opened by incision and the cells were injected in a 5μl volume into the right side 
of the caudate putamen with a Hamilton syringe through a hole drilled to the skull with a 
21G needle. After injection, the wound was wiped with 70% EtOH and sutured. 
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Antisedative drug atipamezole (1 mg/kg) was administered intraperitoneally into operated 
mice together with 1ml of sterile saline. 
The mice were monitored for clinical symptoms and weight loss. Tumor development 
was measured using small animal MRI (Oxford Instruments) and, in the case of CT-2A-
Fluc, with bioluminescence imaging (BLI) (IVIS Lumina II, Perkinelmer). The mice were 
kept under isoflurane anesthesia during imaging. Additionally medetomidine/ketamine 
anesthesia was applied during bioluminescence imaging when deeper sedation was 
required. Pain was medicated with subcutaneous injections of carprofen (5 mg/kg) or 
buprenorphine (0.1 mg/kg). 
The viruses were injected into adult orthotopic glioma-bearing C57BL/6 (I, IV) or glioma-
free BALB/c mice (II, III and unpublished). When applied, intratumoral virus injections 
were made with a small needle through the hole that was punctured for glioma cell 
implantation. Intracranial virus injection into glioma-free BALB/c mice were performed 
through a hole made to the same location as upon the glioma induction. When 
administered directly to the brain, the virus was diluted in 5μl of PBS. Intraperitoneal and 
intravenous (tail vein) virus injections were given in a volume of 100-200μl. 
The mice were observed daily for distress or onset of neurological symptoms. Virus 
related symptoms were graded according to severity. Refined grading scale 0-5 (III and 
unpublished) was as follows: 0, no symptoms; 1, ruffled fur, hunched back, (mild) 
weakness of limbs, optic neuritis; 2, partial paralysis of hind limbs; 3, paralysis of hind or 
front limbs; 4, severe paralysis, tetraplegia; 5, moribund or dead. The mice were sacrificed 
when symptoms of grade 3 or higher were observed. 
Immunohistochemistry (I-IV) 
For immunohistochemical analysis the mice were sacrificed with CO2 followed by 
perfusion with PBS or 4% formalin. The tissues were collected in 4% 
paraformaldehyde/PBS. After overnight immersion fixation at +4°C the tissues were 
transferred to 70% EtOH and kept at +4°C until embedded in paraffin. Paraffin embedded 
tissues were sliced into 7μm sections with rotation microtome and lifted on SuperFrost Plus 
glass slides (Menzel-Gläser), allowed to attach properly by overnight incubation at +37°C 
and kept at +4°C until stained. Antigen retrieval was done by boiling the tissue sections in 
citrate buffer (10mM trisodium citrate dihydrate, pH6). Immunohistochemistry (IHC) for 
the detection of SFV infected tissues was carried out using polyclonal rabbit anti-SFV 
antibody (prepared in our laboratory) that recognized SFV structural proteins, and with 
Vectastain ABC kit (Vector Laboratories). 3,3’-diaminobenzidine (SigmaFast DAB, Sigma-
Aldrich) was used as substrate for the horseradish peroxidase conjugated antibody 
complex to obtain brown precipitate. Delafield’s Hematoxylin (Fluka) was used for 
background staining and Permount (Fischer Scientific) for mounting the stained sections.  
Immunosuppressive combination therapies (I) 
The regime for cyclophoshamide (CPA) combination therapy with VA7-EGFP was as 
follows: CPA was given on days 5 and 11 post tumor induction (3 and 2 mgs respectively), 
and VA7-EGFP (1 × 106 PFU/dose) was administered intravenously on days 6 and 12. 
Rapamycin (diluted in 30% ethanol) combination therapy consisted of i.p. injection of 
rapamycin (5 mg/kg) on days 5–9, 12, and 13, and i.v. administration of VA7-EGFP (1 × 106 
PFU/dose) which was given on days 6–9 and 13 post tumor induction. 
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Neutralizing antibody assay (I) 
Serum was extracted from mouse blood samples using Microvette 500 Z-gel tubes 
(Sarstedt). Five-fold dilution series (1:20, 1:100, 1:500, and 1:2500) of serum samples was 
prepared and 40 μl of each dilution was mixed with 100μl of VA7-EGFP containing 30-50 
PFU of the virus, and incubated 30 minutes at room temperature. Mixtures were added to 
Vero(B) or MBA-13 cells seeded on 12-well-plates. Neutralizing antibody titer was defined 
as reciprocal of the last dilution that inhibited VA7-EFGP infection as visualized by 
fluorescence microscopy. 
PCR amplification of SFV genome from mouse brain sample (III) 
Extraction of virus RNA from mouse brain was done in order to analyze mutations or 
deletions occurring in the miR-124 target element during SFV4-miRT124 infection. Brain 
tissue was collected from a mouse suffering from severe neurological symptoms following 
intraperitoneal SFV4-miRT124 injection. The tissue was frozen with liquid nitrogen and 
stored at -20°C. Total RNA was extracted with GenElute mammalian total RNAminiprep 
kit (Sigma-Aldrich). cDNA was synthetized using Fermentas RevertAid M-MuLV reverse 
transcriptase (Thermo Fisher Scientific) with SFV4-specific primer: 
AATTTTGCGGCCGCTAGCACGTTCTG. 
 
PCR amplification of the miRNA target element region was done with following primers: 
Forward: AATTTTCTCGAGAACCCGATTCCTCC 
Reverse: AGATTGGAATTCCTAACGGATTTTTGTTGT 
 
PCR product was cloned into the pJET1.2 vector using the Fermentas CloneJET PCR 
cloning kit (Thermo Fisher Scientific) and individual clones were verified by sequencing. 
Virus titration from mouse tissues (III) 
For virus titration of mouse organs (part III), tissues (brain and liver) were snap-frozen in 
liquid nitrogen and stored at -70°C. Homogenization was done in 1% bovine serum 
albumin (BSA) containing PBS with Ultra-Turrax (IKA). The homogenate was centrifuged 
at 4500 g, at +4°C for 5 min, and the supernatant was used for titration. Serum was 
separated form blood samples using Microvette 500 Z-gel tubes (Sarstedt). Titration of the 
virus was done using the plaque assay in Vero(B) cells. 
IFN-β quantitation by ELISA (III) 
Quantification of IFN-β was done with Verikine IFNβ ELISA kit (PBL InterferonSource) 
from serum samples and homogenized (as upon virus titration) tissues wich had been 
collected from infected mice following scarification. Samples were dilute 1:2 in buffer 
provided in the kit. 
Statistical analysis (I, III and IV) 
Statistical analysis was done with GraphPad Prism (GraphPad Software) using unpaired, 
two-tailed Student’s t-test (I, III and IV). Mouse surivival was analyzed using Kaplan-Meier 
estimator (GraphPad Prism). 
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5 Results and discussion 
5.1 ATTENUATED SFV VECTOR VA7 SHOWS POOR ONCOLYTIC POTENCY 
AGAINST IMMUNOCOMPETENT MOUSE GLIOMAS (I) 
As shown in previous studies, single systemic dose of replicative SFV vector VA7-EGFP 
resulted in complete eradication of orthotopic U87-Fluc xenografts in an immunodeficient 
mouse model (Heikkilä et al., 2010). These results together with observations of initial 
growth reduction following intratumoral injection of parental rA7(74) virus in an 
immunocompetent BT4C rat glioma model (Määttä et al., 2007) called for a more detailed 
evaluation of VA7 potency in the presence of a fully intact immune system. 
In order to test the oncolytic potency of VA7 in syngenic models, GL261 and CT-2A-FLuc 
gliomas were induced in C57BL/6 mice. In contrast to the previous results in the U87 
model, the growth of GL261 and CT-2A-FLuc gliomas was not affected by intravenous 
VA7-EGFP therapy, and the mice survival was not increased (I, Figures 1c-f). No 
therapeutic effect in the GL261 model was obtained with intracranial VA7-EGFP injection at 
the site of tumor induction (I, Figure 1d). As previously shown (Fazakerley et al., 2006), 
intracranial VA7-EGFP injection resulted in the presence of infected oligodendrocytes in the 
corpus callosum (I, Figure 2d). However, viral replication was not observed in the tumor 
tissue (I, Figure 2d).  
In an attempt to stimulate replication of the virus in GL261 tumors, VA7-EGFP was 
administered in combination with cyclophosphamide (CPA) or rapamycin. These 
immunosuppressive drugs have been shown to increase the oncolytic potency of other 
viruses (Alain et al., 2010; Fulci et al., 2006; Lamfers et al., 2006; Lun et al., 2010a, 2010b, 
2009). Indeed, when given in combination with CPA, VA7-EGFP replication was increased, 
but only in healthy brain tissue surrounding the tumor (I, Figure 2e). Interestingly, CPA 
enhanced VA7-EGFP replication in neurons including cerebellar Purkinje neurons and 
granular neurons (Figure 7). In contrast, combination therapy with rapamycin did not show 
any effect on virus spreading or replication (I, Figure 2f). No therapeutic benefit was gained 
despite a decrease in virus neutralizing antibodies upon CPA or rapamycin combination 
therapy (I, Figures 2a and 2b, table 1).  
CPA-enhanced SFV neurovirulence has been detected before (Bradish et al., 1975a). 
However, CPA has pleiotropic effects on the immune system making interpretation of the 
results difficult. As replication in GL261 gliomas was not increased, the effect appears to be 
neuron specific. CPA is known to reduce IFN-γ secretion of NK cells (Fulci et al., 2006). 
Moreover, IFN-γ-producing NK cells have been shown to mediate SINV clearance from 
neurons (Binder and Griffin, 2001), thus providing a possible explanation for CPA-
enhanced neurovirulence.  
 
 
42 
 
 
 
 
 
Figure 7. Immunohistochemical analysis of C57BL/6JOlaHsd mice cerebellum following VA7-
EGFP infection with or without CPA combination therapy. Left side: cerebellum of a mouse 
administered VA7-EGFP intraperitoneally. Right side: cerebellum of a mouse given 
intraperitoneal VA7-EGFP in combination with cyclophosphamide (CPA). Structural viral proteins 
are stained in brown. (Martikainen et. al., unpublished.) 
 
5.1.1 GL261 resistance to oncolytic VA7 is mediated by innate immune system (I) 
In order to evaluate the role of the adaptive immune system in VA7-therapy failure, the 
GL261 responsiveness was analyzed using athymic C57BL/6 mice (B6.Cg/NTac-Foxn1nu 
NE10) in which the adaptive immune system is impaired. Also in this immunodeficient 
model, VA7-EGFP was not able to replicate in the GL261 glioma tissue, and no survival 
benefit was observed (I, Figure 3). These results indicated that the innate antiviral immune 
responses are responsible for the lack of therapy potency. Although the anti-tumor effect in 
this model could possibly be inhibited because of the missing adaptive immune priming, 
the overall absence of virus in the glioma tissue would argue that the therapy failure was 
mainly due to limited virus replication in the tumor cells.  
As type I IFNs are key mediators of innate antiviral signaling, cell killing by VA7 was 
further analyzed in vitro with or without type I IFN stimulation. Indeed, VA7-EGFP 
replication in GL261 cells was severely restricted when the cells were given exogenous IFN-
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β (I, Figure 4). IFN-β induced a protective antiviral effect also when it was administered 90 
minutes pi. (I, Figure 4a), but not after 4h pi. (I, Figure 4b). This suggested that if SFV 
replication can surpass a certain early threshold, the cell autonomous antiviral defense 
mechanisms are not able to protect the host cell. Notably, it had been observed that after 4h 
pi., SFV disrupts host cell transcription by nsP2-mediated degradation of the RNA 
polymerase II catalytic subunit Rbp1 (Akhrymuk et al., 2012).  
VA7-EGFP showed poor infectivity in confluent GL261 cell culture, indicating that these 
cells can mount sufficient antiviral response also without exogenous type I IFN stimulus (I, 
Figure 5). Supporting this, prominent expression of antiviral OAS and IFN-β was detected 
in infected GL261 cultures (I, Figure 5).  In vitro results with GL261 were in drastic contrast 
to the results obtained using U87 cells, which did not respond to IFN-β stimulation and 
proved to be readily infected also in confluent cultures (I, Figures 4d and 5f). However, U87 
spheroids formed under normal culture conditions were more resistant to infection than 
monolayer cells (I, Figure 6). As an indication of a strong in vivo antiviral milieu in the 
glioma microenvironment, VA7-EGFP-preinfected GL261 cells grew as aggressively as 
uninfected GL261 when implanted intracranially into C57BL/6 mice (I, Figure 7).  
Taken together, the failure of VA7 therapy in the GL261 glioma model cannot be 
ascribed solely to activation of the adaptive immune responses against the virus. The 
observed VA7 resistance of GL261 in vivo, even when preinfected before implantation, and 
the in vitro sensitivity of VA7 to type I IFN even when administered after infection, would 
suggest that type I IFNs expressed by the GL261 cells and/or tumor stromal cells would be 
the main factor responsible for the poor therapy outcome. The exact factors responsible for 
VA7 inhibition in vivo cannot be conclusively defined since analysis of innate cell types 
present in the GL261 microenvironment and measurement of different cytokines in 
response to VA7 therapy remain to be done. However, the key role of type-I IFN response, 
impairing the outcome of VA7 virotherapy, has also been confirmed in other studies using 
immunocompetent CT-26 mouse colon carcinoma (Ruotsalainen et al., 2015) and DBT 
mouse glioma models (Vähä-Koskela et al., 2013).  
5.2 SFV4 VIRULENCE CAN BE ATTENUATED BY INHIBITING NSP3-
AMPHIPHYSIN INTERACTION (II) 
Due to the observed low replication potency of VA7 in type I IFN-producing and 
responsive cancer cells, alternative SFV strains were also tested in this study. Intriguingly, 
tolerance to type I IFN mediated signaling has been reported for virulent SFV clones 
(Deuber and Pavlovic, 2007). Strategies for targeted inhibition of pathogenic replication in 
neurons were however essential and needed to be developed, in order to allow testing of 
such virus in mouse glioma model.  
SFV nsP3 had been shown already previously to be an important mediator of the 
neurovirulent phenotype (Tuittila and Hinkkanen, 2003; Tuittila et al., 2000). Nsp3 has also 
been reported to be involved in multiple host cell protein interactions (Cristea et al., 2006; 
Gorchakov et al., 2008), although their relevance in neuropathogenicity is not well 
characterized. Interestingly, comparison of amino acid sequences between alphaviruses 
SINV, CHKV, SFV, Barmah forest virus, Aura virus, O´nyong-nyong virus, Mayaro virus 
and WEEV indicated that although the C-terminal HVD regions of these alphaviruses are 
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poorly conserved, they all contain proline-rich clusters (II, Figure 1A). Such regions can 
interact with Src homology-3 (SH3) domain-containing proteins which are typically 
associated with cell signaling and membrane trafficking. In addition, proteins encoded by 
several pathogens, e.g. human immunodeficiency virus type 1 encoded Nef, have been 
shown to bind host cell SH3-domain containing proteins (Saksela et al., 1995). Indeed, by 
using SINV, SFV4 and CHKV nsP3 proteins, the proline containing regions were found to 
function as ligands for amphiphysin SH3 domains (II, Figures 1B and 2). Amphiphysins are 
members of the Bin-Amphiphysin-RvsP (BAR) domain-containing superfamily of proteins. 
In particular, the role of amphiphysin-1 in neurovirulence needs further investigation, since 
it is enriched in neuronal cells and associated with vesicular trafficking (Zhang and Zelhof, 
2002), and because alphavirus replication complexes associate with cellular vesicles. 
Amphiphysins were found to be recruited at sites of SFV4 replication (II, Figures 4 and 
5). In mouse neuroblastoma N2A cells, amphiphysin-1 showed strong interaction with 
SFV4 replication sites at 2-6 h time points (II, Figure 5). At the later 10 h time point after 
infection, this interaction was dismantled (II, Figure 5), indicating temporal control of 
amphiphysin binding. In cells infected with SFV (or SINV) mutant with deletion of the 
proline-rich regions (SFVΔP1+P2), only a weak co-localization between amphiphysin and 
the replication complex was detected, indicating that the recruitment of amphiphysin at 
replication sites was strongly associated with the SH3-domain mediated nsP3 interaction 
(II, Figures 6 and 7A). Infection with SFVΔP1+P2 resulted in markedly delayed CPV 
formation and reduced viral RNA synthesis in comparison to wild-type virus (II, Figures 
7C and 8). RNA replication was also attenuated after siRNA silencing of amphiphysin 
expression in HeLa cells. This further supported the importance of amphiphysin during 
SFV and SINV replication (II, Figure 9). The noted weak association with SFVΔP1+P2 
replication complexes indicated that amphiphysins are recruited to these structures in a 
nsP3 independent fashion as well. One explanation could be the association of 
amphiphysins to reorganized membrane structures via the BAR domain that has been 
shown to function in membrane curvature (Habermann, 2004). 
To evaluate the importance of amphiphysin-binding on pathogenesis, neurovirulence of 
SFVΔP1+P2 was compared to wild-type SFV4 in Balb/c mice. In line with the in vitro results, 
mice infected intraperitoneally with SFVΔP1+P2 showed a clearly attenuated phenotype (II, 
Figure 10). Despite this, three out of seven mice infected with SFVΔP1+P2 expressed severe 
neurological symptoms (II, Figure 10). IHC analysis of these mice revealed wild-type -like 
viral replication patterns in the brain (Figure 8), arguing against the necessary role of 
proline-rich regions for SFV4 replication in the CNS. This would also suggest that 
attenuation of neurovirulence was not due to neuron-specific inhibition. However, a 
detailed analysis of tissue types affected by the ΔP1+P2 mutant remains to be conducted.  
To summarize, during SFV infection of HeLa and N2A cells amphiphysins bound to 
nsP3 were involved in replication complex formation. Disruption of this interaction clearly 
weakened replication of the virus, indicating a functional importance of the SH3-binding 
domain of SFV (and SINV). Despite marked reduction in neuropathogenicity after ip. 
injection, SFVΔP1+P2 elicited severe symptoms in a notable fraction of the mice (II, Figure 
10). The symptoms also correlated with viral replication in neuronal cells (Figure 8). It must 
also be noted that both A7(74) and SFV4 strains of SFV contain proline rich regions in their 
nsP3, indicating that differences in this domain cannot explain the differences in 
neurovirulence between these strains.  
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Figure 8. Brain histology of SFV4 and SFVΔP1+P2 -infected BALB/c mice.  SFV4 or SFVΔP1+P2 
(1 x 10^6 PFU) was injected intraperitoneally into an adult BALB/c mouse. The mice were 
sacrificed because of severe neurological symptoms 6 or 5 days post infection (SFV4 and 
SFV4ΔP1+P2 respectively). Examples of infected neurons in the indicated (A-D) cerebellum and 
midbrain/thalamus regions are shown. (Martikainen et. al., unpublished.) 
5.3 MICRORNA TARGETING CAN BE USED FOR NEURON-SPECIFIC 
ATTENUATION OF SFV4 REPLICATION (III) 
Attenuation of neurovirulence and preservation of full replication potency in cancer cells 
would be desired properties for an oncolytic virus in resistant cancer cells. As shown 
previously (part II) deletions or mutation in SFV replicase-encoding genes attenuate 
neurovirulence, but such modifications have a high propability to inhibit replication in 
general. In order to alleviate the neurovirulence problem without deletions in the viral 
genes, feasibility of attenuation by using a miRNA approach was assesed. For this, perfectly 
complementary target elements against neuronally expressed miR-124 were inserted into 
the SFV4 genome (SFV4-miRT124, III). The ultimate aim was to induce decay of viral 
genome in miR-124-expressing neurons while sparing wild-type SFV4 -like replication 
potency in cancer cells. Insertion of target sites was made into the nsP open reading frame 
between SFV4 nsp3 and nsp4 (III, Figure 1). In the construct, the targeting element was also 
flanked on both ends by a nsP2 protease cleavage site, which is naturally present in a single 
copy between nsP3 and nsP4, to allow wild-type like nsP formation during nsP-polyprotein 
processing (III, Figure 1).  
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As proof of concept, miRNA-mediated attenuation was first shown using liver-specific 
miR-122 targeted SFV4 (SFV4-miRT122) and miR-122 expressing human hepatocarcinoma 
Huh7 cells. This study design was applied because cell lines expressing miR-124 were not 
available. SFV4-miRT122 was also designed as a non-neuronally targeted control virus for 
in vivo experiments. As expected, replication of SFV4-miRT122 was inhibited in Huh7 cells 
as was evident from the reduced expression of virus glycoproteins and lower levels of viral 
genomic RNA in the cells (III, Figures 2B and C). Importantly, replication of SFV4-miRT124 
or wild-type SFV4 was not affected in Huh7 cells, indicating that the replication defect of 
SFV4-miRT122 was due to miRT122 insertion. In miR-122 and miR-124 defective BHK-21, 
SFV4 and both of the targeted clones replicated equally well (III, Figure 2). As was detected 
by western blotting of BHK-21 cell lysates, SFV4-miRT122 and SFV4-miRT124 viral nsP3 
and nsP4 proteins were similar in size to the wild-type proteins (III, Figure 2A), indicating 
correct polyprotein processing by nsP2. In addition, the oncolytic potency of target-carrying 
viruses was similar to wild-type SFV4 in miR-122 and miR-124 deficient HeLa, Tera-2 and 
U87 cells in vitro (III, Figure 3), indicating that viral replication was not hampered by the 
genomic insertion of a miRT-element.  
The in vitro results gave an encouraging signal to move further to in vivo experiments. 
For this purpose, adult BALB/c mice were first injected intraperitoneally with SFV4, SFV4-
miRT122 or SFV4-miRT124 (1 x 10^6 PFU). SFV4-miRT124 displayed a clearly attenuated 
phenotype as compared to SFV4-miRT122 or wild-type SFV4 (III, Figure 4A). Equal virus 
titers were measured in serum samples collected from the infected mice (III, Figure 4B). In 
contrast, titers of SFV4-miRT124 in the brain samples were markedly lower (III, Figure 4C), 
indicating a reduced SFV4-miRT124 replication rate specifically in the CNS. Correlating 
with the observed high titers, SFV4 and SFV4-miRT122 also induced detectable IFN-β 
production in the brain (III, Figure 5). In contrast no IFN-β was detected in the brains of 
SFV4-miRT124 infected mice (III, Figure 5). These results are in line with a previous 
observation that the production of proinflammatory cytokines correlates with the strength 
of SFV replication (Tuittila et al., 2004). Attenuation of SFV4-miRT124 neuronal replication 
after intraperitoneal infection was finally confirmed by IHC analysis, revealing that the 
virus was only focally present in the brain, whereas SFV4 and SFV4-miRT122 infections 
were wide-spread (III, Figure 6). Although attenuated in the CNS, SFV4-miRT124 did 
promote immunity against infection with SFV strain L10 in mice (III, Figure 7). This, 
together with the observed serum titers (III, Figure 4B), indicates that SFV4-miRT124 
infectivity in the peripheral compartment was not affected severely if at all. 
While one out of eight mice succumbed to neurological symptoms when SFV4-miRT124 
was given intraperitoneally, six out of six mice developed severe encephalitis following 
intracranial infection, even with the lowest tested amount of the virus (100 PFU; III, Figure 
8). However, the symptoms appeared much later compared to wild-type SFV4 or the liver 
detargeted SFV4-miRT122 construct (III, Figure 8). Despite this, IHC analysis still 
supported neuron-specific attenuation of SFV4-miRT124 as infection was dominantly found 
in oligodendrocytes of the corpus callosum (III, Figure 9A). In comparison, intracranial 
SFV4-miRT122 administration led to a widespread infection including neurons within the 
cerebellum (Purkinje and granular neurons) and in the hippocampus (III, Figure 8B). 
Importantly, the replication pattern restricted to the corpus callosum has been detected also 
following intracranial administration of avirulent A7(74) (Fazakerley et al., 2006). 
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In most cases, sensitizing the virus to host cell miRNAs has been achieved by inserting 
miRT-sequences into the 3’ untranslated region (UTR) of viral transcripts. However, miR-
122 targets inserted either into the 5’ or 3’ UTR regions of SFV4 did not produce significant 
attenuation of the viral replication in Huh7 cells (data not shown).  Insertion of targeting 
element in the nsP reading frame was found to be most effective, and this design was 
therefore chosen for the virus constructs. Because alphavirus 3’UTR tolerates mutations and 
deletions (Kuhn et al., 1990), insertion of target sites inside the nsp reading frame was also 
hypothesized to promote stability of inserted sequences. Indeed, Kueberuwa et al. (2014) 
showed that miRNA target sites inserted into oncolytic SINV structural polyprotein 
reading frame (between C and pE2 genes), had increased stability compared to those 
inserted into 3’UTR when virus was passaged in cell culture.   
The remaining neurovirulence of SFV4-miRT124 particularly upon intracranial 
administration can be associated with infection of spinal cord neurons (data not shown). 
This tropism can probably be explained by the markedly low expression of miR-124 in the 
corpus callosum, medulla and the spinal cord (Pena et al., 2009). If so, the results also 
indicate that the access to spinal cord (cerebrospinal fluid) would be restricted when SFV4 
is given intraperitoneally.  
An alternative explanation is that the virus escaped the engineered miRNA control via 
acquired deletions or mutations in the miRNA target sequence. In order to study whether 
such deletions occured, viral RNA was extracted from the brain tissue of the single mouse 
that had suffered from neurological symptoms after intraperitoneal SFV4-miRT124 
infection. RNA was reverse-transcribed and PCR-amplified with miRNA target site-specific 
primers. Indeed, sequencing the PCR products revealed that one virus clone had deletion of 
all six target sites had been deleted, whereas another clone had deletion of two (out of six) 
target sites. However, a vast majority of the sequenced clones (16/18) showed intact target 
sites, indicating that deletions occurred in a minority of the viruses. Nevertheless, 
alternative target sites and/or combinations of different target sites should be considered, 
because specific neuronal subtypes in the CNS may display different miRNA expression 
patterns. Despite the residual spinal cord infectivity, the ablation of infection in neurons 
following intracranial SFV4-miRT124 injection indicates strong neuroattenuation. The work 
described here showed for the first time that miRNA technology can be applied to a fully 
replicative alphavirus in order to achieve attenuation of replication in the brain while 
retaining the virulent phenotype in cancer cells that is important for oncolysis.  
Interestingly, alphaviruses were recently shown by other authors to be natural targets of 
host miRNAs. It was shown that miR-142-3p, expressed in cells of myeloid-lineage, binds to 
the 3’ UTR region of Eastern equine encephalitis virus RNA genome and restricts its 
replication (Trobaugh et al., 2014).  However, limiting myeloid cell tropism was shown to 
have negative effects on the induction of innate immunity, which subsequently promoted 
the onset of neurologic disease.  Taken together the results demonstrate that, replication of 
SFV4 and other alphaviruses can be inhibited in a cell type-specific manner using 
microRNA-mediated tissue detargeting. However, in order to increase the safety of such 
viral vectors in clinical applications, it is evident that screening for optimal miRNA targets 
or target combinations is still required. 
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5.4 TARGETED SFV4 SHOWS ONCOLYTIC POTENCY AGAINST 
INTERFERON-COMPETENT MOUSE GLIOMAS (IV) 
Given the reported type I IFN resistant phenotype associated with neurovirulent SFV 
(Deuber and Pavlovic, 2007) and the functional miRNA-targeting strategy, the capability of 
SFV4-miRT124 to replicate under antiviral conditions was next evaluated. For this purpose, 
syngeneic C57BL/6 mouse glioma CT-2A-Fluc cells were infected with VA7-EGFP, SFV4 or 
SFV4-miRT124.  
Under normal cell culture conditions, CT-2A-Fluc cells were susceptible to infection with 
all tested SFV clones (IV, Figure 4). However, as compared to VA7-EGFP, infection with 
SFV4-miRT124 induced significantly more IFN-β from the cells (IV, Figure 1A), indicating 
that virulent-type SFV replicase genes facilitate viral replication despite type I IFN 
induction. Further indication of a more robust replication capacity in antiviral conditions 
was achieved by infecting CT-2A-Fluc cells under agarose cover, which inhibits free flow 
and rapid dilution of secreted cytokines. Under these settings, both WT SFV4 and SFV4-
miRT124 were able to form clearly visible plaques (IV, Figure 1C), whereas smaller plaques 
were obtained with VA7-EGFP. Plaque expansion of VA7-EGFP in the presence of Jak 
inhibitor 1 was also enhanced (IV, Figure 1D), further proving that antiviral JAK/STAT-
signaling plays a key role in controlling VA7 replication and spread. Indeed, VA7-EGFP, 
but not SFV4 or SFV4-miRT124, was inhibited also under normal culture conditions in CT-
2A-Fluc cells pretreated with exogenous IFN-β (IV, Figure 1E). Importantly, the results 
indicate that parental wild-type replication potency is conserved in SFV4-miRT124 despite 
the genomic insertion of miRT-element. 
The ability to disrupt JAK/STAT pathway signaling, and particularly phosphorylation of 
STAT1 and STAT2, was proposed by Simmons et al. (2010) to be the molecular mechanism 
behind type-I IFN-tolerant replication that was observed for neurovirulent SINV. In line 
with these results, SFV4, SFV4-miRT124 and L10 exhibited significantly increased STAT1 
inhibition as compared to avirulent A7(74) in Vero(B) cells, which have severe deficiency in 
type I IFN production (IV, Figures 2A and B). Similar inhibition of exogenous IFN-β-
induced STAT1 activation was observed in SFV4 or SFV4-miRT124 infected CT-2A-Fluc 
cells (IV, Figure 2C), indicating that inhibition takes place also in the cells that are capable 
of type I IFN expression.  
STAT1 inhibition in Vero(B) cells occured at notably late, 6 to 8h, time point pi. (IV, 
Figure 2B). However, IFN-β was ineffective against VA7-EGFP in more resistant GL261 
cells already at 4h pi. (I, Figure 4B), which is a lot earlier than the STAT1 inhibitory effects 
in Vero(B) cells. In addition, infection with VA7-EGFP, SFV4 or SFV4-miRT124 induced 
similar baseline STAT1 activation in CT-2A cells (IV, Figure 2C), arguing that SFV is not 
able to dismantle an early or pre-existing antiviral state in the cells. These results obscure 
the relevance of STAT1 inhibition. A similar discrepancy was observed by Yin et al. (2009), 
who hypothesized that JAK/STAT inhibition could play a role in VEEV resistance to IFN-γ-
mediated neuronal clearance, while the replicative potency under the influence of type I 
IFN resulted primarily from VEEV ability to induce host cell translational shut-off.  
Prompted by the wild-type like replication potency of SFV4-miRT124 in vitro, the 
oncolytic potency in vivo was assessed further. For this, CT-2A-Fluc cells were implanted 
into the caudate putamen of C57BL/6 mice (IV, Figures 5E and F). Mice showing clear 
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glioma-derived luminescence signal at day 2 post tumor implantation were administered a 
single intraperitoneal dose (1 x 10^6 PFU) of SFV4-miRT124, VA7-EGFP or PBS at day 3.  
Intriguingly, when compared to PBS or VA7-EGFP-injected groups, the number of mice 
with complete disappearance of the tumor bioluminescence signal in the SFV4-miRT24 
group was clearly increased (13%, 20% and 50% respectively) 6 days after virus injection 
(day 9 post tumor implantation; IV, Figure 5A, Table 1). Tumor growth, as quantified based 
on the luminescence signal, was also significantly reduced in the SFV4-miRT124 treated 
group (IV, Figure 5C). Importantly, mice without detectable Fluc-signal or tumor-related 
symtpoms showed no evidence of tumor mass as imaged with MRI (IV, Figure 5B), 
indicating that the loss of luminescence signal was not due to loss of marker gene 
expression in CT-2A cells. Kaplan-Meier analysis revealed a clear trend for survival benefit 
in SFV4-miRT124 group (IV, Figure 5D). Notably, half of the animals treated with SFV4-
miRT124 showed long-term tumor-free survival. This is indicative of antitumor potency 
that is unprecedented with alphavirus in a syngeneic glioma model.  
Tumor signal disappearance took place six days after virus administration. This time 
point overlaps with the peak viremia in the brain, suggesting that the replicating virus in 
the glioma parenchyma could cause the observed effect. The kinetics of CT-2A-Fluc 
disappearance also coincided with previously observed VA7 tumor replication mediated 
oncolysis of orthotopic U87-Fluc gliomas (Heikkilä et al., 2010). In immunohistochemistry, 
SFV structural proteins were detected in tumors of SFV4-miRT124-treated mice indicating 
that the virus had indeed reached the glioma tissue upon peripheral injection (IV, Figure 6). 
Interestingly, a small number of animals (2/14) in PBS-treated group showed similar CT-
2A-Fluc rejection indicating a natural immunogenicity of the tumor. Thus, potently 
replicating virus infiltrating into the CT-2A tumor could further destroy the 
immunosuppressive tumor microenvironment. Importantly, all mice that survived the 
initial glioma induction became resistant to CT-2A-Fluc re-challenge (IV, Figure 7A). 
Glioma-reactive antibodies were found in the serum samples (IV, Figure 7B), indicating that 
adaptive antitumor immunity had developed in the mice surviving the initial glioma 
induction.  
There are only a few reports on oncolytic viruses showing complete responses in 
immunocompetent glioma models. In the CT-2A model long-term effects have been 
observed following intratumoral administration of neuroattenuated VSV (Muik et al., 2014) 
or oncolytic HSV expressing immunostimulatory Flt3-L (Barnard et al., 2012). In addition, 
GL261 gliomas have been shown to be responsive to intratumorally administered 
Newcastle disease virus (Koks et al., 2015a) and adenovirus DNX-2401 (Jiang et al., 2014). 
The only evidence of peripheral virus administration resulting in long-term glioma 
eradication is provided by Geletneky et al. (2010), who have reported such response 
following repeated dosage of parvovirus H-1 in six out of nine syngeneic RG2 glioma 
bearing rats. Notably, the H-1 administration regime contained 8-12 injections on 
consecutive days. In this context the effect observed with single intraperitoneal SFV4-
miRT124 injection can be considered impressive. 
Finally, cell lines established from human glioblastoma samples from patients operated 
at Kuopio University Hospital were tested for VA7-EGFP and SFV4-miRT124 infectivity 
with or without exogenous human IFN-β. Similar to results in CT-2A-Fluc cells, SFV4-
miRT124 displayed statistically significant increase in cytopathic effect despite IFN-β (IV, 
Figure 8).  Although the difference was not as drastic as with CT-2A-Fluc, the results 
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demonstrate increased oncolytic potency also against human patient-derived glioblastoma 
cells under antiviral type I IFN signaling. In line with similar findings by Alain et al. (2010), 
the results imply that glioblastoma cells in patients can retain type-I IFN signaling 
capability, thus indicating a need for type I IFN-tolerant virus in oncolytic virotherapy of 
such malignancies. 
As noted before in BALB/c mice (III), intraperitoneal infection of SFV4-miRT124 caused 
severe neurological symptoms in a small fraction of mice (IV, Table 1). This correlated with 
virus replication in the spinal cord and brain (IV, Figure 6G). As discussed earlier, there is a 
clear demand for improvements in the construct design. Nevertheless, these results clearly 
demonstrate the increased antitumor efficacy of virulent alphavirus-based oncolytic agents 
compared to naturally attenuated strains. A better understanding of molecular functions of 
alphavirus virulence factors and inclusion of additional targeting motifs will eventually 
allow evaluation of the full potential of SFV as an oncolytic agent. Future work will also 
elucidate the role of adaptive and innate immune system cells in the enhancement or 
inhibition of SFV-mediated oncolytic effect. 
5.4.1 Resistance to type I interferons is not mandatory for SFV neurovirulence (IV) 
In order to elucidate which genomic regions of SFV4 mediate the type I IFN resistant 
phenotype, CT-2A-Fluc cells were infected with chimeric SFV clones (Tuittila et al., 2000) 
with or without the presence of exogenous IFN-β. As evident from Figure 3 (IV), SFV4 and 
clone CMW34 (carrying SFV4 nsp3 and nsp4) were equally capable of killing CT-2A cells 
pretreated with high IFN-β concentration. As both of these viruses are pathogenic in mice 
(Tuittila et al., 2000), the results would suggest a link between the type I IFN resistant 
phenotype and neurovirulence. However CMW3 (carrying solely the SFV4 nsp3) does not 
fit into the model. Although CMW3 has been previously shown to be fully neurovirulent 
(Tuittila et al., 2000), it showed similarly weak cell killing potency of IFN-β treated cells as 
compared to avirulent rA7(74) and CMW12 (carrying SFV4 nsp1 and nsp2). Therefore it is 
concluded that neuronal replication potency, facilitated by SFV4 nsp3, is unrelated to type-I 
IFN tolerance. 
The observed replication phenotype of CMW34 implies that nsP4, which is the viral 
RNA-dependent RNA polymerase, would have an effect on type I IFN resistance of SFV4. 
In the absence of an opal stop codon between the nsp3 and nsp4 genes, nsP4 is the first 
mature virus protein to be produced during SFV infection. The nsP4 protein has been 
observed only in low amounts in infected cells, and it is rapidly degraded by the 
proteosome (de Groot et al., 1991; Merits et al., 2001; Takkinen et al., 1991). A role in 
antiviral signaling evasion would thus seem unlikely. However, recent results indicate that 
CHIKV nsP4 can mediate suppression of eIF2α phosphorylation and thereby support 
translation of viral proteins and robust replication (Rathore et al., 2013). In addition, SFV 
nsP4 associated with the replicase complex has been shown to convert host mRNAs into 5’-
ppp dsRNA, that functions as a ligand for RIG-I and MDA5 and induce IFN-β expression 
(Nikonov et al., 2013). These observations suggest that the specific role of nsP4 in type I IFN 
resistance should be further investigated. 
Taken together, these results indicate that tolerance to type I IFN signaling is not a 
mandatory feature for neurovirulent SFV. However, it cannot be ruled out that such a 
property would be specifically expressed in neuronal cells. If so, then nsP3 would mediate 
type I IFN resistance by neuron-specific action. Type I IFNs have been shown not to be 
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associated with protection against SFV infection in the CNS (Fragkoudis et al., 2007). Thus 
it is likely that the nsP3-mediated molecular mechanism that promotes SFV4 virulence does 
not involve inhibition of type I IFN signaling pathways. To conclude, tolerance to type I 
IFN was shown to be important for the oncolytic potency of SFV (IV) but evidently not for 
neurovirulence, suggesting that neuronal replication of SFV could be attenuated by 
mutating viral genes without sacrificing the type I IFN-tolerant phenotype.  
5.5 NSP3 RNA STRUCTURE IS A POSSIBLE DETERMINANT FOR SFV 
NEUROVIRULENCE (UNPUBLISHED) 
The effect of different SFV4 nsP3 amino acid residues inserted into rA7(74) has been 
studied before (Tuittila and Hinkkanen, 2003; Tuittila et al., 2000).  Insertion of Arg in place 
of opal stop, or a 21-nucleotide-long deletion in the hypervariable domain (both present in 
virulent SFV4) were not enough to recapitulate neurovirulence of rA7(74). Interestingly, 
this avirulent backbone recombinant rA774-V4Del-arg could be turned neurovirulent by 
additional nsP3 mutation pairs V11I + L201F, V11I + D249N or A48E + G70A (Tuittila and 
Hinkkanen, 2003). Although it is possible that these affect virulence by altering nsP3 
protein structure, the effect may have also arisen from altered RNA structure. 
Recent work conducted with alphaviruses presents new cellular mechanisms for 
recognition and degradation of viral RNAs. These support the role of RNA structure on 
alphavirus replication. Hyde et al. (2014) showed that IFN I-inducible host cell factor Ifit1 
binds to VEEV 5’-UTR stem loop structure which restricts replication, and that Ifit1 binding 
can be inhibited by mutations in the VEEV 5’-UTR RNA secondary structure (Hyde et al., 
2014). It has also been shown that Drosha (RNase III, affiliated also in miRNA biogenesis, 
see chapter 2.5.1) is translocated from the nucleus into the cytoplasm during SINV 
infection, and that cytoplasmic Drosha can cleave SINV genomic RNA thus inhibiting 
replication (Shapiro et al., 2014). In addition, Balistreri et al. (2014) showed that SFV early 
transcription is affected by nonsense-mediated mRNA decay pathway components. 
Together these results strongly indicate that alphavirus RNA secondary structures are 
recognized and eliminated by IFN-I-stimulated and IFN-I-independent host factors.  
To study whether SFV neurovirulence is indeed under the control of cell-specific 
regulatory factors sensing viral genome elements and RNA secondary structures, silent 
mutations were incorporated into a SFV clone rA7(74)-V4Del-Arg with additional 
V11I+L201F mutations (“FM14”), shown to be neurovirulent in mice (Tuittila and 
Hinkkanen, 2003).  
Codons of FM14 amino acid residues 11 and 201 were changed as these were the 
residues found to mediate the change from avirulent to virulent phenotype. The mutations 
in the novel “FM14-silent” virus were designed based on their predicted effect on changing 
nsP3 RNA secondary structure (data not shown) as analyzed by RNAfold WebServer 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). Sequence differences between the viruses 
are presented in Table 5. Replication of FM14-silent virus was not affected during virus 
production or plaque titration in BHK-21 or Vero(B) cells, respectively, indicating that the 
induced mutations were tolerated. 
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Table 5. Differences in nsP3 sequences between SFV clones used in the study. Codons of amino 
acids 11 and 201 are shown in parentheses. Silent mutations in”FM14-silent” virus are marked 
with asterisks. Stop: opal stop codon. 
 
 
 
 
To analyze the neuropathogenicity of FM14-silent virus, adult BALB/c mice were 
injected with 1000 PFU of virus intracranially, and the symptoms were monitored. Parental 
FM14, rA7(74)-V4Del-Arg, rA7(74) and SFV4 were used as control viruses. Intriguingly, the 
onset of neurological symptoms in mice infected with FM14-silent was delayed compared 
to parental FM14 (Figure 9). As expected based on earlier results (Tuittila and Hinkkanen, 
2003), the neuropathogenicity of FM14 was similar to wild-type SFV4 (Figure 9). Clones 
rA7(74) and rA7(74)-V4Del-Arg did not cause any severe neurological symptoms in mice 
(Figure 9), which was in line with the earlier work. 
Immunohistochemical analysis of brains collected from symptomatic mice revealed that 
FM14-silent had clearly limited replication potency in the brain (Figure 10), supporting the 
concept of attenuated phenotype. As noted earlier with miRNA-targeted SFV4-miRT124 
(III) and A7(74) (Fazakerley et al., 2006), viral protein was seen mainly in the corpus 
callosum, which gives a strong indication of neuron specific attenuation.  In contrast to 
FM14-silent, both SFV4 and FM14 were disseminated throughout the brain (Figure 10). 
Severe symptoms were delayed but ultimately manifested in all FM14-silent infected mice 
(Figure 10).  Despite this, the observed neuronal replication pattern was severely restricted 
(Figure 10).  
Because alphavirus RNA-dependent RNA polymerase is deficient of proof-reading, 
mutations could be easily reverted or compensated by other mutations during replication. 
Nevertheless, the present results clearly demonstrate that a prominent attenuation of 
neurovirulence can be achieved without tampering with the protein structure. Therefore 
modifications not only to protein but also to RNA structure(s) can be regarded as an 
additional safety enhancing factor in oncolytic therapy virus. Obviously, future work 
should focus on elucidation of the molecular mechanisms behind SFV neurovirulence and 
their possible implications for the design of safe but effective oncolytic alphaviruses. 
 
11 48 70 201 249 387 388 389 390 391 392 393 394 442 449 476
rA7(74) V (GUA) A G L (UUG) D - - - - - - - A T F stop
SFV4 I (AUA) E A F (UUU) N G I A D L A A D A L R
A7(74)-V4Del-Arg V (GUA) A G L (UUG) D G I A D L A A D T F R
FM14 I (AUA) A G F (UUU) D G I A D L A A D T F R
FM14-silent I (AUC)* A G F (UUC)* D G I A D L A A D T F R
nsP3 aa position
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Figure 9. Symptoms and survival of SFV infected BALB/c mice. Adult BALB/c mice were infected 
intracranially with 1000 PFU of the indicated virus. Symptoms were monitored daily and graded 
according to the presented scale (0-5). The mice were sacrificed upon appearance of symptoms 
of grade 3 or higher (Martikainen et al., Unpublished).  
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Figure 10. Brain histology of symptomatic BALB/c mice. Mice were injected intracranially with 
1000 PFU of SFV4, FM14 or FM-14-silent. The mice were sacrificed at the indicated time points 
post infection (pi.) because of severe neurological symptoms. SFV structural proteins were 
detected from paraffin-embedded tissue slices by immunohistochemical analysis (seen as brown 
color). Background staining was performed with hematoxylin. Corpus callosum region indicated 
with dashed line. (Martikainen et al. Unpublished).  
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6 Conclusions 
The starting point for the studies conducted in this thesis was provided by the 
previously observed oncolytic potency of SFV vector VA7 against human glioma xenografts 
in a mouse model. However, tumor xenograft models cannot be considered as clinically 
relevant models for studying oncolytic virotherapy, because they do not reconstitute the 
complex interplay between the virus, tumor and the host immune system. Therefore, 
evaluation of SFV oncolytic efficacy in immunocompetent mouse glioma models was 
conducted. 
The results of this thesis showed that VA7, a vector derived from the naturally avirulent 
SFV strain A7(74),  was unable to infect syngeneic GL261 or CT-2A gliomas in vivo, despite 
the permissiveness of the cells in vitro. The resistance of these glioma cells against the virus 
was mediated mainly by innate immune responses. Further research revealed a significant 
role for type I IFNs in driving the VA7-restricting antiviral signaling. In this respect, VA7 
falls into the category of oncolytic viruses that are engineered or selected to be sensitive to 
type I IFN signaling. Such viruses are commonly used in clinical settings because of their 
enhanced safety. The replication of this type of viruses in cancer cells depends on defective 
antiviral signaling pathways. However, type I IFN deficiencies in a heterogenic population 
of cells forming the malignant glioma cannot be taken for granted. The lack of efficacy in 
clinical trials also indicates that the currently used viruses, although safe, fail to either infect 
or replicate in tumor cells, which is a prerequisite for a therapeutic response. This 
shortcoming clearly warrants closer analysis of virulence and tumor cell permissiveness in 
development of enhanced oncolytic viruses. 
Because alphavirus resistance to type I IFN signaling has been correlated with increased 
neurovirulence, the logical choice was to harness the elevated virulence of SFV4 strain in 
order to enhance the oncolytic potency of SFV-based virotherapy. Novel strategies to 
inhibit SFV4 neuronal replication were however needed before the virus could be utilized 
for therapeutic purposes. The results presented in this thesis show that attenuation of viral 
replication specifically in neurons can be achieved by incorporating miR-124 target sites to 
SFV4 genome (SFV4-miRT124). The advantage of this approach was that mutations or 
deletions in the viral genes were not introduced, thus retaining the SFV4 parental capability 
to replicate in glioma cells despite type I IFN response. Beneficial type I IFN tolerant 
phenotype of SFV4-miRT124 was associated with decreased tumor growth, and complete 
long-term responses in the majority of CT-2A glioma-bearing mice upon administration of 
single systemic dose of the virus. This finding clearly promotes further development of 
oncolytic alphavirus vectors against malignant glioma for clinical trials.  
Despite the inserted miRNA target sites, neuronal replication of SFV4-miRT124 was 
observed in a fraction of infected mice. This could be a result from generation of virus 
escape mutants from which the target sites are deleted, or due to the lack of global miR-124 
expression in the cells/tissue of mouse CNS. The residual neurovirulence of SFV4-miRT124 
could possibly be overcome by screening for additional miRNA target sites that would 
increase the control and ensure the specificity. In addition, alternative strategies to 
attenuate SFV replication in healthy brain tissue should be investigated. Due to the 
generally mild symptoms associated with SFV infection in humans, it can be speculated 
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that neurovirulence would not necessarily present similar problems in human patients as it 
does in mice. It is however obvious, that risks associated with the use of neurotropic SFV 
and the derived neurovirulent strains, need to be carefully evaluated before clinical trials 
can be commenced. 
Intriguingly the findings presented in this thesis indicate that the type I IFN resistance 
and neurovirulence of SFV4 are not mediated by the same viral factors. Although the nsp3 
genomic locus alone seems to bear the major neurovirulence factors, it could not be verified 
as the locus mediating the SFV resistance to type I IFN. Therefore the evolutionary 
relationship between these two traits displayed by SFV4 has no simple explanation. 
Importantly, the results imply that the ability to replicate in neurons and the type-I IFN 
resistance, could be separated in order to engineer novel oncolytic vectors with increased 
efficacy and safety.  
SFV4 nsP3 has previously been identified to be the major factor of neurovirulence. 
Several studies have suggested nsP3 as a major interacting partner with different host 
proteins which are critical for the replication complex assembly and modulation of host cell 
responses to SFV infection. It is granted that screening for nsP3-interacting host factors, 
which are governing SFV4 neuronal replication, is needed to further improve the vector. 
Targeted inhibition of neuron-specific host protein interactions could provide an alternative 
strategy for glioma targeting.  
Results presented in this thesis show that conserved proline-rich regions within the C-
terminal domain of SFV nsP3 bind to SH3 domains of host cell amphiphysins during 
infection. As amphiphysin 1 in particular is enriched in neurons, the importance of the 
nsP3-amphiphysin interaction for neuropathogenesis was investigated. Deletion of the nsP3 
proline-rich domains indeed resulted in an attenuated phenotype. However, the observed 
attenuation was not neuron-specific, thus eliminating use of this approach in brain tumor 
targeting. Interestingly, neurovirulence of SFV was also affected when silent mutations 
altering the RNA secondary structure were induced into the nsp3 gene. The important role 
of alphavirus RNA structure on host cell recognition of the viral genome has been 
implicated by a few recent studies. However, the neuron-specific attenuation in vivo noted 
in this thesis is unprecedented. Identification of the specific genomic regions responsible for 
the neurovirulence and the associated molecular mechanisms should allow additional 
modifications that increase safety without sacrificing the oncolytic potency of SFV4. 
To summarize, type I interferon-mediated antiviral response in glioma tumors presents a 
major hindrance for development of effective oncolytic therapy with alphaviruses. This 
barrier may eventually be overcome by safely harnessing the viral factors, which are 
inherent to neurovirulent SFV strains and that mediate type I IFN-tolerant phenotype. The 
results of this thesis indicate that oncolytic alphaviruses retaining the determinants that 
augment replication specifically in cancer cells could prove effective against highly 
immunosuppressive malignant gliomas also in clinical settings.  
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